[go: up one dir, main page]

WO2009041643A1 - Cdrのアミノ酸置換により抗体の等電点を改変する方法 - Google Patents

Cdrのアミノ酸置換により抗体の等電点を改変する方法 Download PDF

Info

Publication number
WO2009041643A1
WO2009041643A1 PCT/JP2008/067534 JP2008067534W WO2009041643A1 WO 2009041643 A1 WO2009041643 A1 WO 2009041643A1 JP 2008067534 W JP2008067534 W JP 2008067534W WO 2009041643 A1 WO2009041643 A1 WO 2009041643A1
Authority
WO
WIPO (PCT)
Prior art keywords
isoelectric point
antibody
modifying
cdr
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/067534
Other languages
English (en)
French (fr)
Inventor
Tomoyuki Igawa
Hiroyuki Tsunoda
Tatsuhiko Tachibana
Taichi Kuramochi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40511523&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2009041643(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU2008304778A priority Critical patent/AU2008304778B9/en
Priority to MX2015011591A priority patent/MX369784B/es
Priority to EP08834150.8A priority patent/EP2202245B1/en
Priority to RU2010116208/10A priority patent/RU2510400C9/ru
Priority to EP24152324.0A priority patent/EP4339294A3/en
Priority to CN201610952615.3A priority patent/CN106519025B/zh
Priority to BRPI0817294 priority patent/BRPI0817294A2/pt
Priority to ES08834150.8T priority patent/ES2595638T3/es
Priority to CA2700701A priority patent/CA2700701C/en
Priority to MX2010003443A priority patent/MX336725B/es
Priority to CN200880118639.2A priority patent/CN101874042B9/zh
Priority to SI200831671A priority patent/SI2202245T1/sl
Priority to US12/679,922 priority patent/US9096651B2/en
Priority to EP24152321.6A priority patent/EP4368721A3/en
Priority to DK08834150.8T priority patent/DK2202245T3/en
Priority to EP20159129.4A priority patent/EP3689912A1/en
Priority to JP2009534435A priority patent/JP5334319B2/ja
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Priority to TW106122356A priority patent/TWI682938B/zh
Priority to TW097147078A priority patent/TWI599577B/zh
Priority to CL2009000441A priority patent/CL2009000441A1/es
Priority to PE2009000282A priority patent/PE20100268A1/es
Priority to ARP090100676A priority patent/AR070633A1/es
Priority to ARP090100709A priority patent/AR070716A1/es
Publication of WO2009041643A1 publication Critical patent/WO2009041643A1/ja
Priority to IL204242A priority patent/IL204242A/en
Anticipated expiration legal-status Critical
Priority to US14/741,786 priority patent/US9828429B2/en
Priority to IL246040A priority patent/IL246040B/en
Priority to IL251826A priority patent/IL251826B/en
Priority to US15/725,692 priority patent/US11248053B2/en
Priority to IL267546A priority patent/IL267546B/en
Priority to US17/578,524 priority patent/US20220389105A1/en
Priority to ARP230100368A priority patent/AR128541A2/es
Priority to US18/425,859 priority patent/US12122840B2/en
Priority to US18/432,567 priority patent/US12116414B2/en
Priority to US18/883,787 priority patent/US20250011443A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

　本発明者らは、相補性決定領域（CDR）の表面に露出し得る少なくとも１つのアミノ酸残基の電荷を改変することにより、抗体の抗原への結合活性を保持しつつ等電点を改変する方法を提供する。本発明はまた、等電点の改変により多重特異性抗体を精製する方法および等電点が改変された抗体の血漿中薬物動態を改善する方法を提供する。さらに本発明は、等電点が改変された抗体、当該抗体を有効成分として含有する医薬組成物、および、その製造方法を提供する。
PCT/JP2008/067534 2007-09-26 2008-09-26 Cdrのアミノ酸置換により抗体の等電点を改変する方法 Ceased WO2009041643A1 (ja)

Priority Applications (34)

Application Number Priority Date Filing Date Title
AU2008304778A AU2008304778B9 (en) 2007-09-26 2008-09-26 Method of modifying isoelectric point of antibody via amino acid substitution in CDR
MX2015011591A MX369784B (es) 2007-09-26 2008-09-26 Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
EP08834150.8A EP2202245B1 (en) 2007-09-26 2008-09-26 Method of modifying isoelectric point of antibody via amino acid substitution in cdr
RU2010116208/10A RU2510400C9 (ru) 2007-09-26 2008-09-26 Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr
EP24152324.0A EP4339294A3 (en) 2007-09-26 2008-09-26 Method of modifying isoelectric point of antibody via amino acid substitution in cdr
CN201610952615.3A CN106519025B (zh) 2007-09-26 2008-09-26 利用cdr的氨基酸取代来改变抗体等电点的方法
BRPI0817294 BRPI0817294A2 (pt) 2007-09-26 2008-09-26 Método de modificação do ponto isoelétrico de anticorpo via substituição de aminoácido em cdr.
ES08834150.8T ES2595638T3 (es) 2007-09-26 2008-09-26 Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
CA2700701A CA2700701C (en) 2007-09-26 2008-09-26 Method of modifying isoelectric point of antibody via amino acid substitution in cdr
MX2010003443A MX336725B (es) 2007-09-26 2008-09-26 Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
CN200880118639.2A CN101874042B9 (zh) 2007-09-26 2008-09-26 利用cdr的氨基酸取代来改变抗体等电点的方法
SI200831671A SI2202245T1 (sl) 2007-09-26 2008-09-26 Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR
US12/679,922 US9096651B2 (en) 2007-09-26 2008-09-26 Method of modifying isoelectric point of antibody via amino acid substitution in CDR
EP24152321.6A EP4368721A3 (en) 2007-09-26 2008-09-26 Method of modifying isoelectric point of antibody via amino acid substitution in cdr
DK08834150.8T DK2202245T3 (en) 2007-09-26 2008-09-26 A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
EP20159129.4A EP3689912A1 (en) 2007-09-26 2008-09-26 Method of modifying isoelectric point of antibody via amino acid substitution in cdr
JP2009534435A JP5334319B2 (ja) 2007-09-26 2008-09-26 Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法
TW106122356A TWI682938B (zh) 2007-09-26 2008-12-04 利用置換ｃｄｒ區胺基酸來改變抗體等電點的方法
TW097147078A TWI599577B (zh) 2008-09-26 2008-12-04 Methods to alter the isoelectric point of antibodies using amino acid substitutions of CDR regions
ARP090100676A AR070633A1 (es) 2007-09-26 2009-02-26 Metodos para modificar el punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en la region de determinacion de la complementariedad (cdr)
CL2009000441A CL2009000441A1 (es) 2007-09-26 2009-02-26 Metodo para modificar el punto isoelectrico (pl) de un péptido que comprende una region variable de un anticuerpo mediante la sustitucion de aminoacidos en la region cdr, anticuerpos que tiene un pl modificados en las regiones cdr, util para aumentar el tiempo de residencia en el plasma.
PE2009000282A PE20100268A1 (es) 2007-09-26 2009-02-26 Metodos para modificar el punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en la region de determinacion de la complementariedad (cdr)
ARP090100709A AR070716A1 (es) 2007-09-26 2009-02-27 Metodos para modificar el punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en la region de determinacion de la complementariedad (cdr)
IL204242A IL204242A (en) 2007-09-26 2010-03-02 METHOD OF CHANGE ISOELECTRIC POINT OF ANTIBODY BY TRANSMISSION OF AMINIC ACID IN CDR
US14/741,786 US9828429B2 (en) 2007-09-26 2015-06-17 Method of modifying isoelectric point of antibody via amino acid substitution in CDR
IL246040A IL246040B (en) 2007-09-26 2016-06-05 A method for changing the isoelectric point of an antibody through the conversion of an amino acid in cdr
IL251826A IL251826B (en) 2007-09-26 2017-04-20 A method for changing the isoelectric point of an antibody through the conversion of an amino acid in cdr
US15/725,692 US11248053B2 (en) 2007-09-26 2017-10-05 Method of modifying isoelectric point of antibody via amino acid substitution in CDR
IL267546A IL267546B (en) 2007-09-26 2019-06-20 A method for changing the isoelectric point of an antibody through the conversion of an amino acid in cdr
US17/578,524 US20220389105A1 (en) 2007-09-26 2022-01-19 Method of modifying isoelectric point of antibody via amino acid substitution in cdr
ARP230100368A AR128541A2 (es) 2007-09-26 2023-02-16 Métodos para modificar el punto isoeléctrico de anticuerpos mediante la sustitución de aminoácidos en la región de determinación de la complementariedad (cdr)
US18/425,859 US12122840B2 (en) 2007-09-26 2024-01-29 Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US18/432,567 US12116414B2 (en) 2007-09-26 2024-02-05 Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US18/883,787 US20250011443A1 (en) 2007-09-26 2024-09-12 Method of modifying isoelectric point of antibody via amino acid substitution in cdr

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007250165 2007-09-26
JP2007-250165 2007-09-26
JP2007-256063 2007-09-28
JP2007256063 2007-09-28

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/679,922 A-371-Of-International US9096651B2 (en) 2007-09-26 2008-09-26 Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US14/741,786 Continuation US9828429B2 (en) 2007-09-26 2015-06-17 Method of modifying isoelectric point of antibody via amino acid substitution in CDR

Publications (1)

Publication Number Publication Date
WO2009041643A1 true WO2009041643A1 (ja) 2009-04-02

Family

ID=40511523

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/067534 Ceased WO2009041643A1 (ja) 2007-09-26 2008-09-26 Cdrのアミノ酸置換により抗体の等電点を改変する方法

Country Status (22)

Country Link
US (7) US9096651B2 (ja)
EP (5) EP4339294A3 (ja)
JP (11) JP5334319B2 (ja)
KR (1) KR101575914B1 (ja)
CN (2) CN106519025B (ja)
AR (3) AR070633A1 (ja)
AU (1) AU2008304778B9 (ja)
BR (1) BRPI0817294A2 (ja)
CA (1) CA2700701C (ja)
CL (1) CL2009000441A1 (ja)
DK (1) DK2202245T3 (ja)
ES (1) ES2595638T3 (ja)
HU (1) HUE029635T2 (ja)
IL (4) IL204242A (ja)
MX (2) MX369784B (ja)
PE (1) PE20100268A1 (ja)
PL (1) PL2202245T3 (ja)
RU (1) RU2510400C9 (ja)
SI (1) SI2202245T1 (ja)
TW (1) TWI682938B (ja)
WO (1) WO2009041643A1 (ja)
ZA (1) ZA201804148B (ja)

Cited By (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009077569A1 (en) * 2007-12-19 2009-06-25 General Electric Company Biokinetics of fast-clearing polypeptides
WO2010064697A1 (ja) * 2008-12-05 2010-06-10 中外製薬株式会社 抗nr10抗体、およびその利用
WO2010064456A1 (ja) * 2008-12-05 2010-06-10 中外製薬株式会社 抗nr10抗体、およびその利用
WO2010106812A1 (en) * 2009-03-19 2010-09-23 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical formulation containing improved antibody molecules
WO2010131733A1 (ja) 2009-05-15 2010-11-18 中外製薬株式会社 抗axl抗体
US20110033452A1 (en) * 2004-10-26 2011-02-10 Chugai Seiyaku Kabushiki Kaisha Anti-Glypican 3 Antibody Having Modified Sugar Chain
US20110104157A1 (en) * 2008-04-04 2011-05-05 Chugai Seiyaku Kabushiki Kaisha Liver cancer drug
WO2011092989A1 (ja) 2010-01-29 2011-08-04 東レ株式会社 ポリ乳酸系樹脂シート
WO2011108714A1 (ja) 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
US8062635B2 (en) 2003-10-10 2011-11-22 Chugai Seiyaku Kabushiki Kaisha Bispecific antibody substituting for functional proteins
US8124725B2 (en) 2007-12-19 2012-02-28 General Electric Company PDGF-Rβ binders
WO2012142662A1 (en) 2011-04-21 2012-10-26 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using them b
JP2013508308A (ja) * 2009-10-23 2013-03-07 ガーバン インスティテュート オブ メディカル リサーチ 修飾可変ドメイン分子、ならびにその産生および使用方法
JP2013509862A (ja) * 2009-11-04 2013-03-21 メルク・シャープ・アンド・ドーム・コーポレーション 操作型抗ｔｓｌｐ抗体本出願は、米国特許仮出願第６１／２９７，００８号（２０１０年１月２１日出願）、および米国特許仮出願第６１／２５８，０５１号（２００９年１１月４日出願）の利益を主張し、該仮出願は各々、引用によりその全体が本明細書に組み込まれる。
US8431127B2 (en) 2007-12-05 2013-04-30 Chugai Seiyaku Kabushiki Kaisha Method for treating pruritus comprising administering an NR10 antagonist
JP2013518280A (ja) * 2010-01-29 2013-05-20 ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ 凝集体決定法
JP2013529076A (ja) * 2010-05-11 2013-07-18 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｆｇｆｒ２抗体
WO2013118858A1 (ja) 2012-02-09 2013-08-15 中外製薬株式会社 抗体のFc領域改変体
WO2013120929A1 (en) 2012-02-15 2013-08-22 F. Hoffmann-La Roche Ag Fc-receptor based affinity chromatography
JP2013538059A (ja) * 2010-08-24 2013-10-10 アボット・ラボラトリーズ Ｈｉｖコアタンパク質に特異的な抗体及びその使用
US8562991B2 (en) 2008-09-26 2013-10-22 Chugai Seiyaku Kabushiki Kaisha Antibody molecules that bind to IL-6 receptor
JP2013539361A (ja) * 2010-07-29 2013-10-24 ゼンコア インコーポレイテッド 改変された等電点を有する抗体
JP2014507116A (ja) * 2010-12-01 2014-03-27 アルダーバイオ ホールディングス エルエルシー 抗ｎｇｆ組成物およびその使用
WO2015046554A1 (ja) 2013-09-30 2015-04-02 中外製薬株式会社 改変されたヘルパーファージを用いて抗原結合分子を作製する方法
US9028821B2 (en) 2006-06-08 2015-05-12 Chugai Seiyaku Kabushiki Kaisha Method of treating an inflammatory disease comprising administering an NR 10 antibody antagonist
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US9102739B2 (en) 2005-10-14 2015-08-11 Chugai Seiyaku Kabushiki Kaisha Anti-glypican-3 antibody
US9175091B2 (en) 2007-11-15 2015-11-03 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody capable of binding to anexelekto, and use thereof
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
EP2158315B1 (en) 2007-06-25 2016-03-23 ESBATech, an Alcon Biomedical Research Unit LLC Methods of modifying antibodies, and modified antibodies with improved functional properties
WO2016061065A1 (en) * 2014-10-15 2016-04-21 Alexion Pharmaceuticals, Inc. Methods of shifting an isoelectric profile of a protein product and uses thereof
US9334331B2 (en) 2010-11-17 2016-05-10 Chugai Seiyaku Kabushiki Kaisha Bispecific antibodies
WO2016098357A1 (en) 2014-12-19 2016-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
JP5954916B1 (ja) * 2015-04-14 2016-07-20 中外製薬株式会社 Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
US9399680B2 (en) 2007-12-05 2016-07-26 Chugai Seiyaku Kabushiki Kaisha Nucleic acids encoding anti-NR10 antibodies
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
WO2016167263A1 (ja) * 2015-04-14 2016-10-20 中外製薬株式会社 Ｉｌ－３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
WO2017046994A1 (en) 2015-09-18 2017-03-23 Chugai Seiyaku Kabushiki Kaisha Il-8-binding antibodies and uses thereof
US9663574B2 (en) 2014-03-07 2017-05-30 Alexion Pharmaceuticals, Inc. Anti-C5 antibodies having improved pharmacokinetics
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
WO2017104783A1 (en) 2015-12-18 2017-06-22 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
US9688762B2 (en) 2007-09-26 2017-06-27 Chugai Sciyaku Kabushiki Kaisha Modified antibody constant region
US9718882B2 (en) 2010-12-01 2017-08-01 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with P75
US9738713B2 (en) 2010-12-01 2017-08-22 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9765135B2 (en) 2014-12-19 2017-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-C5 antibodies
WO2017217525A1 (en) 2016-06-17 2017-12-21 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
US9868948B2 (en) 2008-04-11 2018-01-16 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9975966B2 (en) 2014-09-26 2018-05-22 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing theraputic agent
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US10022319B2 (en) 2010-01-20 2018-07-17 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing liquid formulations
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
US10253100B2 (en) 2011-09-30 2019-04-09 Chugai Seiyaku Kabushiki Kaisha Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
US10253091B2 (en) 2009-03-19 2019-04-09 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
WO2019088143A1 (ja) * 2017-11-01 2019-05-09 中外製薬株式会社 生物活性が低下した抗体バリアントおよびアイソフォーム
US10604561B2 (en) 2016-09-16 2020-03-31 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use
US10618965B2 (en) 2011-02-25 2020-04-14 Chugai Seiyaku Kabushiki Kaisha Method for altering plasma retention and immunogenicity of antigen-binding molecule
JP2020090504A (ja) * 2013-11-29 2020-06-11 ジェネンテック， インコーポレイテッド 抗体選択装置及び方法
US10683368B2 (en) 2014-11-06 2020-06-16 Hoffmann-La Roche Inc. Fc-region variants with modified FcRn-binding and methods of use
US10697883B2 (en) 2015-05-19 2020-06-30 National Center Of Neurology And Psychiatry Method for determining application of therapy to multiple sclerosis (MS) patient
US10774148B2 (en) 2015-02-27 2020-09-15 Chugai Seiyaku Kabushiki Kaisha Composition for treating IL-6-related diseases
US10782290B2 (en) 2013-06-11 2020-09-22 National Center Of Neurology And Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
US10919953B2 (en) 2012-08-24 2021-02-16 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific Fc region variant
JP2021505533A (ja) * 2017-12-07 2021-02-18 中外製薬株式会社 試料中のポリペプチドの検出または捕捉において使用するための抗体、組成物、および試料中のポリペプチドの検出または捕捉のための方法
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US11053308B2 (en) 2016-08-05 2021-07-06 Chugai Seiyaku Kabushiki Kaisha Method for treating IL-8-related diseases
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
US11124576B2 (en) 2013-09-27 2021-09-21 Chungai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US11214623B2 (en) 2014-09-26 2022-01-04 Chugai Seiyaku Kabushiki Kaisha Antibody capable of neutralizing substance having activity alternative to function of coagulation factor VIII (FVIII)
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
WO2022025030A1 (ja) 2020-07-28 2022-02-03 中外製薬株式会社 新規改変型抗体を含む、針シールドを備えた針付プレフィルドシリンジ製剤
US11260125B2 (en) 2019-11-20 2022-03-01 Chugai Seiyaku Kabushiki Kaisha Anti-IL31RA antibody-containing formulations
US11267868B2 (en) 2013-04-02 2022-03-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
US11352438B2 (en) 2016-09-06 2022-06-07 Chugai Seiyaku Kabushiki Kaisha Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
US11365241B2 (en) 2017-07-27 2022-06-21 Alexion Pharmaceuticals, Inc. High concentration anti-C5 antibody formulations
JP2022544818A (ja) * 2019-08-20 2022-10-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 二重特異性抗体の製剤最適化
US11649262B2 (en) 2015-12-28 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
RU2803096C2 (ru) * 2017-06-05 2023-09-06 Янссен Байотек, Инк. Способы модификации поверхностного заряда для получения биспецифических антител
US11820793B2 (en) 2011-11-30 2023-11-21 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
US11827699B2 (en) 2011-09-30 2023-11-28 Chugai Seiyaku Kabushiki Kaisha Methods for producing antibodies promoting disappearance of antigens having plurality of biological activities
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US11891434B2 (en) 2010-11-30 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US11891432B2 (en) 2018-03-15 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use
JP2024059658A (ja) * 2019-01-03 2024-05-01 アムジエン・インコーポレーテツド 安定性及び生産力価を向上させるためのモノクローナル抗体操作
US12128101B2 (en) 2017-10-26 2024-10-29 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS)
US12168697B2 (en) 2015-12-25 2024-12-17 Chugai Seiyaku Kabushiki Kaisha Bispecific antibodies which bind blood coagulation factor VIII and have enhanced activity, and methods of use thereof for treating bleeding and associated conditions
US12240893B2 (en) 2018-10-30 2025-03-04 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH)
US12312394B2 (en) 2018-06-28 2025-05-27 Alexion Pharmaceuticals, Inc. Methods of producing anti-C5 antibodies
US12371505B2 (en) 2016-12-21 2025-07-29 Teneobio, Inc. Anti-BCMA heavy chain-only antibodies
US12404320B2 (en) 2018-05-31 2025-09-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients
US12459992B2 (en) 2016-05-27 2025-11-04 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
US12460014B2 (en) 2016-04-28 2025-11-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
US12460012B2 (en) 2018-06-04 2025-11-04 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS) in pediatric patients

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19613491B4 (de) 1996-04-04 2005-07-21 Junghans Uhren Gmbh Transponder-Armbanduhr
WO2004111233A1 (ja) * 2003-06-11 2004-12-23 Chugai Seiyaku Kabushiki Kaisha 抗体の製造方法
WO2009041062A1 (ja) * 2007-09-28 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 血漿中動態が改善されたグリピカン３抗体
US8951973B2 (en) * 2008-08-29 2015-02-10 Kevin Burton Controlled-released peptide formulations
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
KR20150002894A (ko) * 2010-03-11 2015-01-07 리나트 뉴로사이언스 코프. ｐＨ 의존성 항원 결합을 갖는 항체
AU2011337697B2 (en) 2010-11-30 2016-10-27 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
US9522595B2 (en) 2011-01-27 2016-12-20 Irobot Defense Holdings, Inc. Small unmanned ground vehicle
WO2013022855A1 (en) * 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
DK2766392T3 (da) * 2011-10-10 2019-10-07 Xencor Inc Fremgangsmåde til oprensning af antistoffer
US20140322216A1 (en) 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
RU2014141536A (ru) 2012-03-16 2016-05-10 Регенерон Фармасьютикалз, Инк. Мыши, которые продуцируют антигенсвязывающие белки с зависимыми от величины ph характеристиками связывания
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
PL2883449T3 (pl) 2012-03-16 2018-07-31 Regeneron Pharmaceuticals, Inc. Przekształcone histydyną łańcuchy lekkie przeciwciał i genetycznie zmodyfikowane gryzonie do wytwarzania tych przeciwciał
CN107361011B (zh) 2012-03-16 2021-08-27 瑞泽恩制药公司 制备表达ph敏感性免疫球蛋白序列的非人动物的方法
WO2014052462A2 (en) * 2012-09-25 2014-04-03 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
WO2014110601A1 (en) 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
CA2906927C (en) 2013-03-15 2021-07-13 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
WO2014146575A1 (en) 2013-03-19 2014-09-25 Beijing Shenogen Pharma Group Ltd. Antibodies and methods for treating estrogen receptor-associated diseases
RU2714967C2 (ru) * 2013-12-27 2020-02-21 Чугаи Сейяку Кабусики Кайся Способ очистки антител с низкой изоэлектрической точкой
TWI674274B (zh) 2014-03-17 2019-10-11 日商田邊三菱製藥股份有限公司 抗體－飛諾莫接合物
EP3119490B1 (en) 2014-03-21 2021-09-08 F. Hoffmann-La Roche AG In vitro prediction of in vivo half-life of antibodies
PL3122781T3 (pl) 2014-03-28 2020-06-15 Xencor, Inc. Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3
CN106459959A (zh) 2014-05-08 2017-02-22 中外制药株式会社 对gpc3靶向治疗剂疗法有效的患者施用的gpc3靶向治疗剂
US10183994B2 (en) * 2014-06-30 2019-01-22 Merck Patent Gmbh Anti-TNFα antibodies with pH-dependent antigen binding for improved target clearence
UA121550C2 (uk) 2014-07-10 2020-06-25 ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД. АНТИТІЛО, ЯКЕ ЗВ'ЯЗУЄ A<font face="Symbol">b</font>-ПРОТОФІБРИЛИ
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
TN2017000222A1 (en) 2014-11-26 2018-10-19 Xencor Inc Heterodimeric antibodies that bind cd3 and cd38
HRP20211273T1 (hr) 2014-11-26 2021-11-12 Xencor, Inc. Heterodimerna protutijela koja vežu cd3 i cd20
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
JP6962819B2 (ja) * 2015-04-10 2021-11-05 アディマブ， エルエルシー 親ホモ二量体抗体種からのヘテロ二量体多重特異性抗体の精製方法
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
PL3294775T3 (pl) * 2015-05-12 2021-12-13 Regeneron Pharmaceuticals, Inc. Oznaczanie czystości białka multimerycznego
JP7096667B2 (ja) 2015-07-01 2022-07-06 中外製薬株式会社 Ｇｐｃ３標的治療剤が有効である患者に投与されるｇｐｃ３標的治療剤
EP3328883A1 (en) 2015-07-31 2018-06-06 GlaxoSmithKline Intellectual Property Development Limited Antibody variants
JP2017057201A (ja) * 2015-09-16 2017-03-23 田辺三菱製薬株式会社 抗体−フィノマー複合体を含む医薬組成物
EP3387013B1 (en) 2015-12-07 2022-06-08 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
WO2017201731A1 (en) 2016-05-27 2017-11-30 Beijing Vdjbio Co., Ltd. Antibodies, composition and kits comprising same, and methods of use thereof
HRP20241447T1 (hr) 2016-06-14 2025-01-03 Xencor, Inc. Bispecifična inhibitor antitijela kontrolnih točaka
DK3475303T3 (da) * 2016-06-27 2021-05-31 Morphosys Ag Anti-cd19-antistofformuleringer
CN116063545A (zh) 2016-06-28 2023-05-05 Xencor股份有限公司 结合生长抑素受体2的异源二聚抗体
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
KR102562519B1 (ko) 2016-10-14 2023-08-02 젠코어 인코포레이티드 IL-15/IL-15Rα FC-융합 단백질 및 PD-1 항체 단편을 포함하는 이중특이성 이종이량체 융합 단백질
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018139623A1 (en) 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
AU2018255938A1 (en) 2017-04-21 2019-10-31 Staten Biotechnology B.V. Anti-ApoC3 antibodies and methods of use thereof
JP7268011B2 (ja) * 2017-06-05 2023-05-02 ヤンセン バイオテツク，インコーポレーテツド 二重特異性抗体製造のための表面電荷を工学的に操作する方法
KR20250007003A (ko) 2017-06-20 2025-01-13 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
US11084863B2 (en) 2017-06-30 2021-08-10 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
JP7039694B2 (ja) 2017-10-31 2022-03-22 スターテン・バイオテクノロジー・ベー・フェー 抗ａｐｏｃ３抗体およびその使用方法
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
JP2021502100A (ja) 2017-11-08 2021-01-28 ゼンコア インコーポレイテッド 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
US11319355B2 (en) 2017-12-19 2022-05-03 Xencor, Inc. Engineered IL-2 Fc fusion proteins
WO2019195623A2 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
US11505595B2 (en) 2018-04-18 2022-11-22 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
MX2020010910A (es) 2018-04-18 2021-02-09 Xencor Inc Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
MX2021002057A (es) * 2018-08-21 2021-07-21 Bioatla Inc Proteinas condicionalmente activas con selectividad de ph.
MA53822A (fr) 2018-10-03 2021-08-11 Xencor Inc Protéines de fusion fc hétérodimères d'il -12
SG11202109406TA (en) 2019-03-01 2021-09-29 Xencor Inc Heterodimeric antibodies that bind enpp3 and cd3
MX2021013646A (es) * 2019-05-09 2022-01-31 Merus Nv Dominios variantes para las proteínas multimerizantes y su separación.
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
IL296089A (en) * 2020-06-19 2022-11-01 Hoffmann La Roche Antibodies binding to cd3
MX2023001962A (es) 2020-08-19 2023-04-26 Xencor Inc Composiciones anti-cd28.
WO2022072846A2 (en) 2020-10-02 2022-04-07 Impossible Foods Inc. Transgenic plants with altered fatty acid profiles and upregulated heme biosynthesis
WO2022072833A2 (en) 2020-10-02 2022-04-07 Impossible Foods Inc. Expression constructs and methods of genetically engineering cells
WO2022087458A1 (en) 2020-10-23 2022-04-28 Asher Biotherapeutics, Inc. Fusions with cd8 antigen binding molecules for modulating immune cell function
EP4213158A1 (en) 2020-11-13 2023-07-19 Ahead Biocomputing, Co. Ltd Information processing device, information processing method, recording medium recording information processing program, and information processing system
CA3212665A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
WO2022192586A1 (en) 2021-03-10 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
US20240182558A1 (en) * 2021-04-23 2024-06-06 Amgen Inc. Modified anti-tslp antibodies
EP4340866A4 (en) * 2021-05-19 2025-05-21 Asher Biotherapeutics, Inc. Il-21 polypeptides and targeted constructs
WO2023008404A1 (ja) * 2021-07-26 2023-02-02 デンカ株式会社 ヒト化抗体を含む試薬
JP2024534148A (ja) * 2021-08-27 2024-09-18 ペプトロン インコーポレイテッド 新規抗ｍｕｃ１抗体およびその用途
WO2023174897A1 (en) * 2022-03-14 2023-09-21 Helmholtz Zentrum Muenchen - Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Composition comprising an antibody which binds to human srrm2 present on the cell surface of a target cell
CN120818056A (zh) * 2024-04-15 2025-10-21 北京伟德杰生物科技有限公司 抗白介素6受体的抗体及其应用
WO2025224095A1 (en) 2024-04-22 2025-10-30 Recordati Netherlands Bv Use of inhibitors of il-6 or il-6r for treating graft versus host disease in a subject

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006004663A2 (en) * 2004-06-25 2006-01-12 Medimmune, Inc. Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
WO2007114319A1 (ja) * 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法

Family Cites Families (648)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US285030A (en) * 1883-09-18 William e
US105889A (en) * 1870-08-02 Improvement in the manufacture of artificial stone
US136485A (en) * 1873-03-04 Improvement in centrifugal machines
US121022A (en) * 1871-11-14 Improvement in harness-fviountings
SE370449B (ja) 1970-08-29 1974-10-14 Philips Nv
JPS5334319B2 (ja) 1971-12-28 1978-09-20
JPS4961501U (ja) 1972-09-06 1974-05-30
JPS525973Y2 (ja) 1973-09-06 1977-02-08
JPS5717624B2 (ja) 1974-04-17 1982-04-12
JPS59878B2 (ja) 1975-09-04 1984-01-09 松下電工株式会社 感知器
JPS5334319U (ja) 1976-08-28 1978-03-25
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
JPS5623853Y2 (ja) 1977-11-26 1981-06-04
JPS5717624U (ja) 1980-07-07 1982-01-29
JPS5787446U (ja) 1980-11-18 1982-05-29
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4444878A (en) 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
EP0091539B2 (en) 1982-03-31 1996-11-27 Ajinomoto Co., Inc. Gene coding for interleukin-2 polypeptide, recombinant DNA carrying said gene, cell lines possessing the recombinant DNA,and method for producing interleukin-2 using said cells
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS59162441U (ja) 1983-04-14 1984-10-31 千代田紙業株式会社 吹込口を有する重包包装
JPS6088703U (ja) 1983-11-24 1985-06-18 リョービ株式会社 自動鉋盤における切削屑排出装置
JPH0210879Y2 (ja) 1984-10-25 1990-03-16
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPH0234615Y2 (ja) 1986-08-08 1990-09-18
JPH06104071B2 (ja) 1986-08-24 1994-12-21 財団法人化学及血清療法研究所 第▲ｉｘ▼因子コンホメ−シヨン特異性モノクロ−ナル抗体
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
JPS63149900A (ja) 1986-12-15 1988-06-22 Toshiba Corp 半導体メモリ
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5004697A (en) * 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
JPH01144991A (ja) 1987-12-02 1989-06-07 Kagaku Oyobi Ketsusei Riyouhou Kenkyusho 血液凝固第８因子の精製方法
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US5322678A (en) 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
JP2516002Y2 (ja) 1988-03-25 1996-11-06 ホーチキ株式会社 煙感知器
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5126250A (en) 1988-09-28 1992-06-30 Eli Lilly And Company Method for the reduction of heterogeneity of monoclonal antibodies
CA1332367C (en) 1988-09-28 1994-10-11 Richard Mark Bartholomew Method for the reduction of heterogeneity of monoclonal antibodies
IL89491A0 (en) 1988-11-17 1989-09-10 Hybritech Inc Bifunctional chimeric antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB8916400D0 (en) 1989-07-18 1989-09-06 Dynal As Modified igg3
JPH0636741B2 (ja) 1989-11-08 1994-05-18 帝人株式会社 ヒト・プロテインｃの分離方法
EP0505357B1 (en) 1989-12-11 1999-03-10 Immunomedics, Inc. Method for antibody targeting of diagnostic or therapeutic agents
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5130129A (en) 1990-03-06 1992-07-14 The Regents Of The University Of California Method for enhancing antibody transport through capillary barriers
TW212184B (ja) 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
JPH05184383A (ja) 1990-06-19 1993-07-27 Dainabotsuto Kk 二重特異性抗体
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH05199894A (ja) 1990-08-20 1993-08-10 Takeda Chem Ind Ltd 二重特異性抗体および抗体含有薬剤
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
ATE181575T1 (de) 1991-04-25 1999-07-15 Chugai Pharmaceutical Co Ltd Rekombinierte humane antikörper gegen den humanen interleukin 6-rezeptor
JPH05304992A (ja) 1991-06-20 1993-11-19 Takeda Chem Ind Ltd ハイブリッド・モノクローナル抗体および抗体含有薬剤
US5468634A (en) 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
DE69229477T2 (de) 1991-09-23 1999-12-09 Cambridge Antibody Technology Ltd., Melbourn Methoden zur Herstellung humanisierter Antikörper
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
JPH0767688B2 (ja) 1992-01-21 1995-07-26 近畿コンクリート工業株式会社 Ｐｃコンクリートパネル
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
JPH05203652A (ja) 1992-01-28 1993-08-10 Fuji Photo Film Co Ltd 抗体酵素免疫分析法
JPH05213775A (ja) 1992-02-05 1993-08-24 Otsuka Pharmaceut Co Ltd Ｂｆａ抗体
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
CA2131151A1 (en) 1992-03-24 1994-09-30 Kevin S. Johnson Methods for producing members of specific binding pairs
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
SG48760A1 (en) 1992-07-24 2003-03-18 Abgenix Inc Generation of xenogenetic antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ZA936260B (en) 1992-09-09 1994-03-18 Smithkline Beecham Corp Novel antibodies for conferring passive immunity against infection by a pathogen in man
BR9204244A (pt) 1992-10-26 1994-05-03 Cofap Ferro fundido cinzento
CA2149025A1 (en) 1992-12-01 1994-06-09 Man Sung Co Humanized antibodies reactive with l-selectin
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
EP0690873B1 (en) 1993-03-19 2003-06-11 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
WO1995001571A1 (en) 1993-07-01 1995-01-12 Baxter Diagnostics Inc. Process for the preparation of factor x depleted plasma
GB9314271D0 (en) 1993-07-09 1993-08-18 Inst Of Cancer The Research Cell growth factor receptors
UA40577C2 (uk) 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
AU7967294A (en) 1993-10-06 1995-05-01 Board Of Regents, The University Of Texas System A monoclonal anti-human il-6 receptor antibody
IL107742A0 (en) 1993-11-24 1994-02-27 Yeda Res & Dev Chemically-modified binding proteins
AU690171B2 (en) 1993-12-03 1998-04-23 Medical Research Council Recombinant binding proteins and peptides
US6214613B1 (en) 1993-12-03 2001-04-10 Ashai Kasei Kogyo Kabushiki Kaisha Expression screening vector
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5945311A (en) 1994-06-03 1999-08-31 GSF--Forschungszentrumfur Umweltund Gesundheit Method for producing heterologous bi-specific antibodies
DE122009000068I2 (de) 1994-06-03 2011-06-16 Ascenion Gmbh Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
US8017121B2 (en) 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
NZ288883A (en) 1994-07-11 1998-12-23 Univ Texas Conjugates comprising coagulation factors
CN1156460A (zh) 1994-07-13 1997-08-06 中外制药株式会社 抗人白细胞介素-8的重构人抗体
TW416960B (en) 1994-07-13 2001-01-01 Chugai Pharmaceutical Co Ltd Reshaped human antibody to human interleukin-8
US6048972A (en) 1994-07-13 2000-04-11 Chugai Pharmaceutical Co., Ltd. Recombinant materials for producing humanized anti-IL-8 antibodies
EP0770628B9 (en) 1994-07-13 2007-02-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
JP3865418B2 (ja) 1994-07-13 2007-01-10 中外製薬株式会社 ヒトインターロイキン−８に対する再構成ヒト抗体
US6309636B1 (en) 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
ATE552012T1 (de) 1994-10-07 2012-04-15 Chugai Pharmaceutical Co Ltd Hemmung des abnormalen wachstums von synovialzellen durch il-6-antagonisten als wirkstoff
HU227708B1 (en) 1994-10-21 2011-12-28 Chugai Pharmaceutical Co Ltd Use of anti-interleukin-6-receptor antibodies mr-16 and pm-1 and derivatives thereof for producing pharmaceutical preparation for treating diseases caused by il-6 production
JPH10511085A (ja) 1994-12-02 1998-10-27 カイロン コーポレイション 二重特異性抗体を用いる免疫応答を促進する方法
US6485943B2 (en) 1995-01-17 2002-11-26 The University Of Chicago Method for altering antibody light chain interactions
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
DE69611288T2 (de) 1995-02-28 2001-07-19 The Procter & Gamble Company, Cincinnati Herstellung eines kohlensäurefreien getränks mit verbesserter mikrobieller stabilität
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
KR100654645B1 (ko) 1995-04-27 2007-04-04 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE283926T1 (de) 1995-09-11 2004-12-15 Kyowa Hakko Kogyo Kk Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP3032287U (ja) 1996-06-10 1996-12-17 幸喜 高橋 人 形
US20020147326A1 (en) 1996-06-14 2002-10-10 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
NZ333650A (en) * 1996-07-19 2000-02-28 Amgen Inc Analogs of cationic proteins like NT-3 (neurotrophin-3) and BDNF (brain derived neurotrophic factor) that are circulated more readily due to a lower isoelectric point and a lower protein charge relative to the native protein
US7247302B1 (en) 1996-08-02 2007-07-24 Bristol-Myers Squibb Company Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
CA2262405A1 (en) 1996-08-02 1998-02-12 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
WO1998013388A1 (en) 1996-09-26 1998-04-02 Chugai Seiyaku Kabushiki Kaisha Antibody against human parathormone related peptides
JPH10165184A (ja) 1996-12-16 1998-06-23 Tosoh Corp 抗体、遺伝子及びキメラ抗体の製法
US5990286A (en) 1996-12-18 1999-11-23 Techniclone, Inc. Antibodies with reduced net positive charge
US6025158A (en) 1997-02-21 2000-02-15 Genentech, Inc. Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1998042377A1 (fr) 1997-03-21 1998-10-01 Chugai Seiyaku Kabushiki Kaisha Substances servant a la prevention ou au traitement de maladies liees a la cellule-t sensibilisee contenant comme principe actif des antagonistes de l'il-6
US7365166B2 (en) * 1997-04-07 2008-04-29 Genentech, Inc. Anti-VEGF antibodies
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
WO1998050431A2 (en) 1997-05-02 1998-11-12 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US20030207346A1 (en) 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
DE19725586C2 (de) 1997-06-17 1999-06-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper
CN1068524C (zh) 1997-06-23 2001-07-18 叶庆炜 一种治疗顽症牛皮癣的药物
US5980893A (en) 1997-07-17 1999-11-09 Beth Israel Deaconess Medical Center, Inc. Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis
US6207805B1 (en) 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
US20020187150A1 (en) 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
ATE395933T1 (de) 1997-08-15 2008-06-15 Chugai Pharmaceutical Co Ltd Präventiva oder arzneien enthaltend neutralisierende anti-il6-rezeptor antikörper zur reduktion urinären proteins bei systemischen lupus erythematosus
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
ES2293691T3 (es) 1997-10-03 2008-03-16 Chugai Seiyaku Kabushiki Kaisha Anticuerpo humano natural.
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
ATE383875T1 (de) 1998-03-17 2008-02-15 Chugai Pharmaceutical Co Ltd Prophylaktische oder therapeutische mittel gegen entzündliche erkrankungen des verdauungstraktes enthaltend antagonistische il-6 rezeptor antikörper
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
PL343322A1 (en) 1998-04-03 2001-08-13 Chugai Pharmaceutical Co Ltd Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
HK1044159A1 (zh) 1998-12-01 2002-10-11 蛋白质设计实验室股份有限公司 抗γ-干扰素的人化抗体
DE69934967T2 (de) 1998-12-08 2007-12-06 Biovation Ltd. Verfahren zur verminderung der immunogenität von proteinen
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CN1763097B (zh) 1999-01-15 2011-04-13 杰南技术公司 具有改变的效应功能的多肽变体
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
AU2006225302B2 (en) 1999-03-25 2010-08-12 AbbVie Deutschland GmbH & Co. KG Human antibodies that bind human IL-12 and methods for producing
DK1188830T3 (da) 1999-06-02 2010-04-26 Chugai Pharmaceutical Co Ltd Nyt hæmopoietinreceptorprotein NR10
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
SE9903895D0 (sv) 1999-10-28 1999-10-28 Active Biotech Ab Novel compounds
AU2001249835A1 (en) 2000-04-03 2001-10-15 Oxford Glycosciences (Uk) Ltd. Diagnosis and treatment of alzheimer's disease
AU2001266272B2 (en) 2000-05-03 2005-09-15 Medigene Ag Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
CN101134107A (zh) 2000-05-15 2008-03-05 史密丝克莱恩比彻姆公司 抗血栓剂
US20020103345A1 (en) 2000-05-24 2002-08-01 Zhenping Zhu Bispecific immunoglobulin-like antigen binding proteins and method of production
US7732133B2 (en) 2000-07-17 2010-06-08 Chugai Seiyaku Kabushiki Kaisha Screening methods for biologically active ligands
AU2011244851A1 (en) 2000-07-27 2011-11-24 The John Hopkins University School Of Medicine Promyostatin peptides and methods of using same
DK1325033T3 (da) 2000-10-10 2010-04-06 Genentech Inc Inhibering af komplement C5 aktivering til behandlingen og forebyggelsen af forsinket xenograf- eller akut vaskulær afstødning
US6875432B2 (en) 2000-10-12 2005-04-05 Genentech, Inc. Reduced-viscosity concentrated protein formulations
WO2002033073A1 (en) 2000-10-20 2002-04-25 Chugai Seiyaku Kabushiki Kaisha Degraded agonist antibody
WO2002034292A1 (fr) 2000-10-25 2002-05-02 Chugai Seiyaku Kabushiki Kaisha Agents preventifs ou therapeutiques contre le psoriasis renfermant l'antagoniste de l'il-6 comme substance active
JP4889187B2 (ja) 2000-10-27 2012-03-07 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する血中ｍｍｐ−３濃度低下剤
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
RU2179862C1 (ru) 2000-12-26 2002-02-27 Общество с ограниченной ответственностью Научно-производственный центр "МедБиоСпектр" Лекарственное средство для предотвращения отторжения трансплантата, моноклональное антитело к cd3-антигену т-лимфоцитов человека, гибридома и способ лечения больных, имеющих реакцию острого отторжения трансплантата после пересадки почки
CA2440221C (en) 2001-03-07 2013-02-05 Merck Patent Gesellschaft Mit Beschraenkter Haftung Expression technology for proteins containing a hybrid isotype antibody moiety
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
CA2443903C (en) * 2001-04-13 2018-03-20 Biogen, Inc. Antibodies to vla-1
ES2399028T3 (es) 2001-06-22 2013-03-25 Chugai Seiyaku Kabushiki Kaisha Inhibidores de la proliferación celular que contienen anticuerpo anti-glipicano 3
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
CN100391537C (zh) 2001-08-17 2008-06-04 建南德克公司 结合至c5和c5a但不阻止c5b形成的补体途径抑制剂
US20030049203A1 (en) 2001-08-31 2003-03-13 Elmaleh David R. Targeted nucleic acid constructs and uses related thereto
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
DK1443961T3 (da) 2001-10-25 2009-08-24 Genentech Inc Glycoprotein-sammensætninger
US20030190705A1 (en) 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
DE10156482A1 (de) 2001-11-12 2003-05-28 Gundram Jung Bispezifisches Antikörper-Molekül
DK2308888T3 (en) 2001-11-14 2017-06-06 Janssen Biotech Inc Anti-IL-6 Antibodies, Compositions, Methods and Uses
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
EP3960855A1 (en) 2001-12-28 2022-03-02 Chugai Seiyaku Kabushiki Kaisha Method for stabilizing proteins
CN101843895A (zh) 2002-01-18 2010-09-29 津莫吉尼蒂克斯公司 新的细胞因子zcytor17配体
AU2003280410B8 (en) 2002-01-18 2009-04-23 Zymogenetics, Inc. Cytokine receptor zcytor17 multimers
BR0307548A (pt) 2002-02-11 2006-01-17 Genentech Inc Método de produção de uma variante de anticorpo, variante de anticorpo, composição, ácido nucléico isolado, vetor, célula hospedeira, processo para a produção de uma variante de anticorpo e método de determinação do coeficiente de associação de antìgeno de um anticorpo
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
US20030216551A1 (en) 2002-03-08 2003-11-20 Diabetogen Biosciences Inc. Fully human anti-CD3 monoclonal antibodies
US7736652B2 (en) 2002-03-21 2010-06-15 The Regents Of The University Of California Antibody fusion proteins: effective adjuvants of protein vaccination
US8030461B2 (en) 2002-04-15 2011-10-04 Chugai Seiyaku Kabushiki Kaisha Methods for constructing scDb libraries
US20040018573A1 (en) 2002-04-18 2004-01-29 Power Scott D Production of functional antibodies in filamentous fungi
AU2003235833A1 (en) 2002-04-26 2003-11-10 Chugai Seiyaku Kabushiki Kaisha Method of screening agonistic antibody
JP2004086862A (ja) 2002-05-31 2004-03-18 Celestar Lexico-Sciences Inc タンパク質相互作用情報処理装置、タンパク質相互作用情報処理方法、プログラム、および、記録媒体
EP1509770B1 (en) 2002-05-31 2014-07-09 GE Healthcare Bio-Sciences AB Method of coupling binding agents to a substrate surface
WO2003107218A1 (ja) 2002-05-31 2003-12-24 セレスター・レキシコ・サイエンシズ株式会社 相互作用予測装置
AU2003248652A1 (en) 2002-06-12 2003-12-31 Genencor International, Inc. Methods for improving a binding characteristic of a molecule
US20060141456A1 (en) 2002-06-12 2006-06-29 Cynthia Edwards Methods and compositions for milieu-dependent binding of a targeted agent to a target
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
CA2872136C (en) 2002-07-18 2017-06-20 Merus B.V. Recombinant production of mixtures of antibodies
TW200407335A (en) 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
AU2003264009A1 (en) 2002-08-15 2004-03-03 Epitomics, Inc. Humanized rabbit antibodies
CN1678744B (zh) 2002-08-30 2010-05-26 财团法人化学及血清疗法研究所 人的抗人白细胞介素-6抗体以及所述抗体的片段
EP1549747A4 (en) 2002-09-16 2006-08-23 Wyeth Corp ACTIVATION OF MYOSTATIN METALLOPROTEASE, AND METHODS OF MODULATION OF MYOSTATIN ACTIVITY
EP2042517B1 (en) 2002-09-27 2012-11-14 Xencor, Inc. Optimized FC variants and methods for their generation
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1562972B1 (en) 2002-10-15 2010-09-08 Facet Biotech Corporation ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS
GB0224082D0 (en) 2002-10-16 2002-11-27 Celltech R&D Ltd Biological products
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
NZ541050A (en) 2002-12-16 2010-06-25 Genmab As Human monoclonal antibodies against interleukin 8 (IL-8)
ATE553128T1 (de) 2002-12-24 2012-04-15 Rinat Neuroscience Corp Anti-ngf-antikörper und verfahren zu ihrer verwendung
WO2004060919A1 (ja) 2002-12-26 2004-07-22 Chugai Seiyaku Kabushiki Kaisha ヘテロ受容体に対するアゴニスト抗体
ATE431423T1 (de) 2003-01-21 2009-05-15 Chugai Pharmaceutical Co Ltd Verfahren zum screening der leichten kette eines antikörpers
WO2004068931A2 (en) 2003-02-07 2004-08-19 Protein Design Labs Inc. Amphiregulin antibodies and their use to treat cancer and psoriasis
US20040223970A1 (en) 2003-02-28 2004-11-11 Daniel Afar Antibodies against SLC15A2 and uses thereof
CN1780850A (zh) 2003-02-28 2006-05-31 抗基因公司 凝集素在促进糖蛋白和抗原分子的低聚反应中的用途
CN100353997C (zh) 2003-02-28 2007-12-12 中外制药株式会社 稳定的含蛋白质的制剂
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
NZ577166A (en) 2003-03-04 2010-10-29 Alexion Pharma Inc Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
WO2004085475A2 (en) 2003-03-24 2004-10-07 Zymogenetics, Inc. Anti-il-20 antibodies and binding partners and methods of using in inflammation
GB2400851B (en) 2003-04-25 2004-12-15 Bioinvent Int Ab Identifying binding of a polypeptide to a polypeptide target
JP2004321100A (ja) 2003-04-25 2004-11-18 Rikogaku Shinkokai ＩｇＧのＦｃ領域を含むタンパク質の変異体
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
EP1639009B1 (en) 2003-05-30 2013-02-27 Merus B.V. Fab library for the preparation of a mixture of antibodies
RS20181002A1 (sr) 2003-05-30 2018-12-31 Genentech Inc Tretman sa anti-vegf antitelima
JP5110877B2 (ja) 2003-06-02 2012-12-26 ワイス・エルエルシー 神経筋障害を処置するための、コルチコステロイドと組み合わせたミオスタチン（ｇｄｆ８）インヒビターの使用
PL1631313T3 (pl) 2003-06-05 2015-08-31 Genentech Inc Terapia skojarzona zaburzeń z komórek B
WO2004111233A1 (ja) 2003-06-11 2004-12-23 Chugai Seiyaku Kabushiki Kaisha 抗体の製造方法
EP1636264A2 (en) 2003-06-24 2006-03-22 MERCK PATENT GmbH Tumour necrosis factor receptor molecules with reduced immunogenicity
CA2531482A1 (en) 2003-06-30 2005-01-20 Centocor, Inc. Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
WO2005023193A2 (en) 2003-09-04 2005-03-17 Interleukin Genetics, Inc. Methods of treating endometriosis
US20050152894A1 (en) 2003-09-05 2005-07-14 Genentech, Inc. Antibodies with altered effector functions
US7297336B2 (en) 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
JP2005101105A (ja) 2003-09-22 2005-04-14 Canon Inc 位置決め装置、露光装置、デバイス製造方法
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
WO2005035753A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
EP1693448A4 (en) 2003-10-14 2008-03-05 Chugai Pharmaceutical Co Ltd DOUBLE SPECIFICITY ANTIBODY FOR FUNCTIONAL PROTEIN SUBSTITUTION
JP2007531707A (ja) 2003-10-15 2007-11-08 ピーディーエル バイオファーマ， インコーポレイテッド ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変
JP4651541B2 (ja) 2003-10-17 2011-03-16 中外製薬株式会社 中皮腫治療剤
PT1689777E (pt) 2003-11-05 2007-05-31 Ares Trading Sa Processo para a purificação da proteína de ligação a il-18
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
EP1697415A1 (en) 2003-11-12 2006-09-06 Biogen Idec MA Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
EP1701979A2 (en) 2003-12-03 2006-09-20 Xencor, Inc. Optimized antibodies that target the epidermal growth factor receptor
JP2007512846A (ja) 2003-12-04 2007-05-24 ゼンコー・インコーポレイテッド 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
DK2383295T3 (en) 2003-12-10 2015-06-15 Squibb & Sons Llc Ip-10 antibodies and uses thereof
LT2418220T (lt) 2003-12-10 2017-10-10 E. R. Squibb & Sons, L.L.C. Interferono-alfa antikūnai ir jų panaudojimas
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
US20050136051A1 (en) 2003-12-22 2005-06-23 Bernard Scallon Methods for generating multimeric molecules
US20050249723A1 (en) 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
US8568725B2 (en) 2003-12-25 2013-10-29 Kyowa Hakko Kirin Co., Ltd. Method of treating transplant rejection with an anti-CD40 antibody
AU2004309050B2 (en) 2003-12-30 2010-10-14 Merck Patent Gmbh IL-7 fusion proteins
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
KR20060120229A (ko) 2003-12-31 2006-11-24 쉐링-프라우 리미티드 중화 에피토프계 성장 증진 백신
MX350383B (es) 2004-01-09 2017-09-04 Pfizer Anticuerpos contra madcam.
KR101149242B1 (ko) 2004-01-12 2012-05-25 어플라이드 몰리큘라 에볼류션, 인코포레이티드 Ｆｃ 영역 변이체
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
ATE464908T1 (de) 2004-02-11 2010-05-15 Warner Lambert Co Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
ATE452147T1 (de) 2004-02-19 2010-01-15 Genentech Inc Antikörper mit korrigierten cdr
JP4695133B2 (ja) 2004-03-23 2011-06-08 イーライ リリー アンド カンパニー 抗ミオスタチン抗体
KR20070035482A (ko) 2004-03-24 2007-03-30 추가이 세이야쿠 가부시키가이샤 인터로킨-6 안타고니스트를 활성성분으로 함유하는내이장해 치료제
CA2561264A1 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
EP3736295A1 (en) 2004-03-24 2020-11-11 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleukin-6 receptor
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005112564A2 (en) 2004-04-15 2005-12-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Germline and sequence variants of humanized antibodies and methods of making and using them
AU2005247301B2 (en) 2004-04-16 2011-08-18 Macrogenics, Inc. FC&gamma;RIIB-specific antibodies and methods of use thereof
KR100620554B1 (ko) 2004-06-05 2006-09-06 한국생명공학연구원 Ｔａｇ-72에 대한 인간화 항체
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
MXPA06014684A (es) 2004-06-18 2007-02-12 Ambrx Inc Novedosos polipeptidos de enlace antigeno y sus usos.
MX2007000105A (es) 2004-07-06 2007-07-18 Bioren Inc Mutagenesis look-through para crear polipeptidos alterados con propiedades mejoradas.
DE102004032634A1 (de) 2004-07-06 2006-02-16 Sms Demag Ag Verfahren und Einrichtung zum Messen und Regeln der Planheit und/oder der Bandspannungen eines Edelstahlbandes oder einer Edelstahlfolie beim Kaltwalzen in einem Vielwalzengerüst, insbesondere in einem 20-Walzen-Sendizimir-Walzwerk
ES2353967T3 (es) 2004-07-09 2011-03-08 Chugai Seiyaku Kabushiki Kaisha Anticuerpo anti-glipicano 3 .
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
EP1919950A1 (en) 2004-07-15 2008-05-14 Xencor, Inc. Optimized fc variants
EA012464B1 (ru) 2004-08-04 2009-10-30 Эпплайд Молекьюлар Эволюшн, Инк. Антитело против cd20 и его применение
JP2008510007A (ja) 2004-08-16 2008-04-03 メディミューン，インコーポレーテッド 抗体依存性細胞性細胞傷害活性が増強されたＥｐｈ受容体Ｆｃ変異体
AU2005285347A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
MX2007002856A (es) 2004-09-02 2007-09-25 Genentech Inc Metodos para el uso de ligandos receptores de muerte y anticuerpos c20.
MX2007002883A (es) 2004-09-13 2007-06-15 Macrogenics Inc Anticuerpos humanizados contra el virus de nilo occidental y usos terapeuticos y profilacticos del mismo.
CA2580319A1 (en) 2004-09-14 2006-03-23 National Institute For Biological Standards And Control Vaccine
US20060074225A1 (en) 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
EP1810979B1 (en) 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. STABILIZED HUMAN IgG4 ANTIBODIES
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
EP1805320B1 (en) 2004-10-22 2014-09-03 Amgen Inc. Methods for refolding of recombinant antibodies
AU2005333602B2 (en) 2004-10-22 2012-04-12 Medimmune, Llc High affinity antibodies against HMGB1 and methods of use thereof
WO2006046751A1 (ja) 2004-10-26 2006-05-04 Chugai Seiyaku Kabushiki Kaisha 糖鎖改変抗グリピカン３抗体
WO2006050166A2 (en) 2004-10-29 2006-05-11 Medimmune, Inc. Methods of preventing and treating rsv infections and related conditions
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
CA2587766A1 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
EP2325207B1 (en) 2004-11-12 2017-03-15 Xencor, Inc. FC variants with altered binding to FCRN
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
CN101098890B (zh) 2004-11-12 2012-07-18 赞科股份有限公司 对FcRn的结合被改变的Fc变体
WO2006065208A1 (en) 2004-12-14 2006-06-22 Ge Healthcare Bio-Sciences Ab Purification of immunoglobulins
US8329186B2 (en) 2004-12-20 2012-12-11 Isu Abxis Co., Ltd Treatment of inflammation using BST2 inhibitor
EP2208783A1 (en) 2004-12-22 2010-07-21 Chugai Seiyaku Kabushiki Kaisha Method of producing an antibody using a cell in which the function of fucose transporter is inhibited
US8728828B2 (en) 2004-12-22 2014-05-20 Ge Healthcare Bio-Sciences Ab Purification of immunoglobulins
US20090087478A1 (en) 2004-12-27 2009-04-02 Progenics Pharmaceuticals (Nevada), Inc. Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
HUE026688T2 (en) 2004-12-28 2016-07-28 Univ Di Genova Monoclonal antibody to NKG2A
EP1847602B1 (en) 2005-01-12 2014-04-23 Kyowa Hakko Kirin Co., Ltd. STABILIZED HUMAN IgG2 ANTIBODIES
US20060275282A1 (en) 2005-01-12 2006-12-07 Xencor, Inc. Antibodies and Fc fusion proteins with altered immunogenicity
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
JP2008530132A (ja) 2005-02-14 2008-08-07 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１ｒａアンタゴニストを用いて皮膚障害を治療する方法
US20060263357A1 (en) 2005-05-05 2006-11-23 Tedder Thomas F Anti-CD19 antibody therapy for autoimmune disease
JP5153613B2 (ja) 2005-03-18 2013-02-27 メディミューン，エルエルシー 抗体のフレームワーク・シャッフル
EP1871808A2 (en) 2005-03-31 2008-01-02 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
JP5057967B2 (ja) 2005-03-31 2012-10-24 中外製薬株式会社 ｓｃ（Ｆｖ）２構造異性体
CA2603408C (en) 2005-03-31 2018-08-21 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
SI1876236T1 (sl) 2005-04-08 2014-11-28 Chugai Seiyaku Kabushiki Kaisha Protitelo, ki funkcionalno nadomesti faktor viii za koagulacijo krvi
SG161281A1 (en) 2005-04-15 2010-05-27 Genentech Inc Hgf beta chain variants
AU2006236417B2 (en) 2005-04-20 2011-02-03 Amgen Fremont Inc. High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies
NL1031674C2 (nl) 2005-04-25 2007-04-26 Pfizer Antilichamen tegen myostatine.
EP1874816A4 (en) 2005-04-26 2010-08-25 Medimmune Inc MODULATION OF THE ANTIBODY EFFECTOR FUNCTION BY "HINGE" DOMENGINE ENGINEERING
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
PE20061324A1 (es) 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
EP1896503B1 (en) 2005-05-31 2014-10-29 Board of Regents, The University of Texas System IgG1 ANTIBODIES WITH MUTATED Fc PORTION FOR INCREASED BINDING TO FcRn RECEPTOR AND USES TEHEREOF
KR101367544B1 (ko) 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
EP3348639A3 (en) 2005-06-10 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Sc(fv)2 site-directed mutant
JP2008546805A (ja) 2005-06-23 2008-12-25 メディミューン，エルエルシー 最適な凝集および断片化プロフィールを有する抗体製剤
WO2007008943A2 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
CA2614766A1 (en) 2005-07-11 2007-01-18 Macrogenics, Inc. Methods of treating autoimmune disease using humanized anti-cd16a antibodies
PT1912675E (pt) 2005-07-25 2014-05-09 Emergent Product Dev Seattle Moléculas de ligaçao especificas para cd37 e especificas para cd20
ES2579602T3 (es) 2005-08-10 2016-08-12 Macrogenics, Inc. Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de uso de estos
SI1915397T1 (sl) 2005-08-19 2015-05-29 Wyeth Llc Antagonistična protitelesa proti GDF-8 in uporabe pri zdravljenju ALS in drugih obolenj, povezanih z GDF-8
EP1789435B1 (en) 2005-09-12 2010-02-24 Industry Foundation of Chonnam National University A method for production of mature natural killer cell
JP2009510102A (ja) 2005-09-29 2009-03-12 ヴァイラル ロジック システムズ テクノロジー コーポレーション 免疫調節組成物およびその使用
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
EA015589B1 (ru) 2005-10-06 2011-10-31 Эли Лилли Энд Компани Антитела против миостатина и их применение
AU2006302254B2 (en) 2005-10-06 2011-05-26 Xencor, Inc. Optimized anti-CD30 antibodies
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
JP5014143B2 (ja) 2005-10-14 2012-08-29 学校法人福岡大学 膵島移植における移植膵島障害抑制剤
RU2450830C2 (ru) 2005-10-21 2012-05-20 Чугаи Сейяку Кабусики Кайся Средства для лечения кардиопатии
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
WO2007060411A1 (en) 2005-11-24 2007-05-31 Ucb Pharma S.A. Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
TW200803894A (en) 2005-11-25 2008-01-16 Univ Keio Prostate cancer therapeutic agents
JP2009517404A (ja) 2005-11-28 2009-04-30 メディミューン，エルエルシー Ｈｍｇｂ１および／またはｒａｇｅのアンタゴニストならびにその使用方法
BRPI0619056A2 (pt) 2005-11-28 2011-09-20 Genmab As anticorpo monovalente, método para preparar e produzir um antcorpo monovalente, construção de ácido nucleico, célula hospedeira, imunoconjugado, uso de um anticorpo monovalente, e, composição farmacêutica
BRPI0619747B8 (pt) 2005-12-12 2021-05-25 Ac Immune Sa método para produzir uma composição de vacina terapêutica, construto antigênico, composição de vacina, usos de um construto antigênico, e, método para preparar e produzir um medicamento para o tratamento de uma condição ou doença associada com amilóide
WO2007074880A1 (ja) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
WO2007133816A2 (en) 2006-01-10 2007-11-22 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists
PT2463305T (pt) 2006-01-12 2016-07-19 Alexion Pharma Inc Anticorpos para ox-2/cd200 e seus usos
JP5033643B2 (ja) 2006-01-27 2012-09-26 学校法人慶應義塾 脈絡膜血管新生を伴う疾患の治療剤
EP1988922A4 (en) 2006-02-03 2010-06-02 Medimmune Llc PROTEIN FORMULATIONS
US20070190056A1 (en) 2006-02-07 2007-08-16 Ravi Kambadur Muscle regeneration compositions and uses therefor
JP4179517B2 (ja) 2006-02-21 2008-11-12 プロテノバ株式会社 イムノグロブリン親和性リガンド
US8674073B2 (en) 2006-02-21 2014-03-18 Protenova Co., Ltd. Immunoglobulin affinity ligand
ES2530637T3 (es) 2006-03-02 2015-03-04 Alexion Pharma Inc Prolongación de la supervivencia de un aloinjerto por inhibición de la actividad del complemento
SI2596807T1 (sl) 2006-03-08 2016-03-31 Archemix Llc Komplement vezavni aptameri in sredstva proti C5, uporabni pri zdravljenju očesnih motenj
EP3167888B1 (en) 2006-03-15 2024-05-01 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
US7951918B2 (en) 2006-03-17 2011-05-31 Biogen Idec Ma Inc. Stabilized polypeptide compositions
JP4294082B2 (ja) 2006-03-23 2009-07-08 協和発酵キリン株式会社 ヒトトロンボポエチン受容体に対するアゴニスト抗体
PL2004688T5 (pl) 2006-03-23 2014-09-30 Bioarctic Neuroscience Ab Ulepszone przeciwciała wobec protofibryli oraz ich zastosowania
JP2009532027A (ja) 2006-03-28 2009-09-10 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗ｉｇｆ−１ｒ抗体およびその使用
CN105177091A (zh) 2006-03-31 2015-12-23 中外制药株式会社 用于纯化双特异性抗体的抗体修饰方法
CN101495146B (zh) 2006-04-07 2012-10-17 国立大学法人大阪大学 肌肉再生促进剂
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
BRPI0711908B8 (pt) 2006-05-25 2021-05-25 Glaxo Group Ltd anticorpo anti-interleucina-18 humanizado, composição farmacêutica, uso de um anticorpo anti-interleucina 18, e, método de produção de um anticorpo.
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
PT2041177E (pt) 2006-06-02 2012-03-05 Regeneron Pharma Anticorpos com elevada afinidade para o receptor il-6 humano
SI2047863T1 (sl) 2006-06-08 2013-11-29 Chugai Seiyaku Kabushiki Kaisha Sredstvo za preprečevanje ali zdravljenje vnetne bolezni
ES2415655T3 (es) 2006-06-15 2013-07-26 The Board Of Trustees Of The University Of Arkansas Anticuerpos monoclonales que reconocen selectivamente Metanfetamina y compuestos similares a Metanfetamina
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
TW200817006A (en) 2006-06-23 2008-04-16 Smithkline Beecham Corp IL-8 receptor antagonist
AR062223A1 (es) 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
CA2658557C (en) 2006-08-14 2015-12-01 Xencor, Inc. Optimized antibodies that target cd19
US8063188B2 (en) 2006-09-05 2011-11-22 Eli Lilly And Company Anti-myostatin antibodies
DK2066349T3 (da) 2006-09-08 2012-07-09 Medimmune Llc Humaniseret anti-cd19-antistoffer og anvendelse heraf i behandling af tumorer, transplantation og autoimmune sygdomme
AU2007299843B2 (en) 2006-09-18 2012-03-08 Xencor, Inc Optimized antibodies that target HM1.24
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
WO2008121160A2 (en) 2006-11-21 2008-10-09 Xencor, Inc. Optimized antibodies that target cd5
CN100455598C (zh) 2006-11-29 2009-01-28 中国抗体制药有限公司 功能人源化抗人cd20抗体及其应用
JP5036295B2 (ja) 2006-12-25 2012-09-26 京セラ株式会社 半導体素子の実装構造体
WO2008091798A2 (en) 2007-01-22 2008-07-31 Xencor, Inc. Optimized ca9 antibodies and methods of using the same
BRPI0806812B8 (pt) 2007-01-23 2021-09-14 Chugai Pharmaceutical Co Ltd Agente para suprimir reação de rejeição crônica e uso de um inibidor de il-6
CA2669412A1 (en) 2007-01-23 2008-07-31 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
US20110236374A1 (en) 2007-01-24 2011-09-29 Kyowa Hakko Kirin Co., Ltd. Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
WO2008098115A2 (en) 2007-02-07 2008-08-14 Xencor, Inc. Optimized igf-1r antibodies and methods of using the same
EP2069404B1 (en) 2007-02-14 2011-01-05 Vaccinex, Inc. Humanized anti-cd100 antibodies
KR101520110B1 (ko) 2007-02-23 2015-05-18 머크 샤프 앤드 돔 코포레이션 가공된 항-ＩＬ-23ｐ19 항체
WO2008114733A1 (ja) 2007-03-16 2008-09-25 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-4抗体
MX2009010181A (es) 2007-03-22 2009-12-04 Novartis Ag Antigenos c5 y usos de los mismos.
CN101679974B (zh) 2007-03-27 2015-09-30 航道生物技术有限责任公司 包含抗体替代轻链序列的构建体和文库
WO2008119353A1 (en) 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
CL2008001071A1 (es) 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
WO2008143954A2 (en) 2007-05-14 2008-11-27 Biogen Idec Ma Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
EP2708557A1 (en) 2007-05-30 2014-03-19 Xencor, Inc. Method and compositions for inhibiting CD32B expressing cells
WO2008145141A1 (en) 2007-05-31 2008-12-04 Genmab A/S Method for extending the half-life of exogenous or endogenous soluble molecules
EP4119579A1 (en) 2007-05-31 2023-01-18 Genmab A/S Stable igg4 antibodies
CN103435696B (zh) 2007-06-25 2016-10-12 艾斯巴技术-诺华有限责任公司 修饰抗体的方法和具有改善的功能性质的修饰抗体
BRPI0813287A2 (pt) 2007-06-25 2014-12-30 Esbatech Alcon Biomed Res Unit Planejamento e otimização baseados na sequência de anticorpos de cadeia única
KR101527342B1 (ko) 2007-07-17 2015-06-09 메다렉스, 엘.엘.시. 글리피칸-3에 대한 단클론 항체
EP2174667B1 (en) 2007-07-26 2017-01-04 Osaka University Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient
WO2009026117A2 (en) 2007-08-16 2009-02-26 Glaxo Group Limited Novel compounds
CA2697612A1 (en) 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Anti-igf-1r antibodies and uses thereof
CA2697922A1 (en) 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Compositions that bind multiple epitopes of igf-1r
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
MX2010002683A (es) 2007-09-14 2010-03-26 Amgen Inc Poblaciones de anticuerpos homogeneos.
US9096651B2 (en) * 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
WO2009041734A1 (ja) 2007-09-26 2009-04-02 Kyowa Hakko Kirin Co., Ltd. ヒトトロンボポエチン受容体に対するアゴニスト抗体
CA2978687C (en) 2007-09-26 2020-02-18 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
EP2206775B1 (en) 2007-09-26 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-il-6 receptor antibody
WO2009041062A1 (ja) 2007-09-28 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 血漿中動態が改善されたグリピカン３抗体
CA2701155C (en) 2007-10-02 2016-11-22 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for graft-versus-host disease comprising interleukin 6 receptor inhibitor as active ingredient
KR100888133B1 (ko) 2007-10-02 2009-03-13 에스케이에너지 주식회사 4종의 금속성분으로 구성된 다성분계 비스무스몰리브데이트 촉매 제조방법 및 상기촉매를 이용하여1,3-부타디엔을 제조하는 방법
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009053368A1 (en) 2007-10-22 2009-04-30 Merck Serono S.A. Single ifn-beta fused to a mutated igg fc fragment
JP2011500756A (ja) 2007-10-22 2011-01-06 メルク セローノ ソシエテ アノニム Ｆｃ融合タンパク質を精製する方法
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
CN101918452A (zh) 2007-11-15 2010-12-15 中外制药株式会社 与Anexelekto结合的单克隆抗体及其利用
CN104162155A (zh) 2007-12-05 2014-11-26 中外制药株式会社 搔痒症治疗药
MX337081B (es) 2007-12-05 2016-02-10 Chugai Pharmaceutical Co Ltd Anticuerpo anti-nr10 y su uso.
US7982017B2 (en) 2007-12-18 2011-07-19 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
BR122021010656B1 (pt) 2007-12-26 2022-07-19 Xencor, Inc Anticorpo anti-tnf e composição farmacêutica
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
DK2235064T3 (en) 2008-01-07 2016-01-11 Amgen Inc A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
AU2008347438B2 (en) 2008-01-18 2013-08-29 Stichting Sanquin Bloedvoorziening Methods for increasing the therapeutic efficacy of immunoglobulin G class 3 (IgG3) antibodies
CA2712432C (en) 2008-01-29 2018-09-25 Ablynx N.V. Methods to stabilize single variable domains
KR20160070165A (ko) 2008-02-08 2016-06-17 메디뮨 엘엘씨 Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체
AU2015227424A1 (en) 2008-04-11 2015-10-01 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
LT2708559T (lt) 2008-04-11 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Antigeną surišanti molekulė, galinti pakartotinai prisijungti prie dviejų ar daugiau antigeno molekulių
CA2722600C (en) 2008-05-01 2014-01-21 Amgen Inc. Anti-hepcidin antibodies and methods of use
BRPI0911960B1 (pt) 2008-05-14 2022-03-22 Agriculture Victoria Services Pty Limited Uso de angiogenina no preparo de uma composição, suplemento alimentar ou nutracêutico para promover o crescimento e melhora muscular
US10717781B2 (en) 2008-06-05 2020-07-21 National Cancer Center Neuroinvasion inhibitor
HRP20150799T1 (hr) 2008-08-05 2015-09-11 Novartis Ag Sastavi i postupci za protutijela protiv komplementnog proteina c5
PL2853545T3 (pl) 2008-09-17 2016-12-30 Przeciwciało swoiste wobec IgE
JP5028372B2 (ja) 2008-09-26 2012-09-19 京セラドキュメントソリューションズ株式会社 画像処理装置、画像処理方法及び画像処理プログラム
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JP5229888B2 (ja) 2008-09-30 2013-07-03 独立行政法人産業技術総合研究所 弱酸性域での易解離性を向上したプロテインａ変異型タンパク質及び抗体捕捉剤
NZ592611A (en) 2008-10-10 2013-01-25 Emergent Product Dev Seattle A single chain fusion protein that binds to tcr complex and does not induce or induces a minimally detectable cytokine release
ES2828721T3 (es) 2008-10-14 2021-05-27 Genentech Inc Variantes de inmunoglobulina y usos de las mismas
CN104940917A (zh) 2008-11-10 2015-09-30 阿雷克森制药公司 用于治疗补体相关障碍的方法和组合物
JP5807300B2 (ja) 2008-11-18 2015-11-10 株式会社シノテスト 試料中のｃ反応性蛋白質の測定方法及び測定試薬
NZ602166A (en) 2008-11-25 2014-02-28 Alder Biopharmaceuticals Inc Antibodies to il-6 and use thereof
WO2010064090A1 (en) 2008-12-02 2010-06-10 Pierre Fabre Medicament Process for the modulation of the antagonistic activity of a monoclonal antibody
AR074438A1 (es) 2008-12-02 2011-01-19 Pf Medicament Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal
KR20160062207A (ko) 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
AR074777A1 (es) 2008-12-19 2011-02-09 Glaxo Group Ltd Proteinas de union a antigeno
EP2385955B1 (en) 2009-01-12 2020-08-12 CytomX Therapeutics, Inc. Modified antibody compositions, methods of making and using thereof
WO2010080065A1 (en) 2009-01-12 2010-07-15 Ge Healthcare Bio-Sciences Ab Affinity chromatography matrix
US20120100140A1 (en) 2009-01-23 2012-04-26 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
US20100292443A1 (en) 2009-02-26 2010-11-18 Sabbadini Roger A Humanized platelet activating factor antibody design using anti-lipid antibody templates
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
WO2010107109A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
SG10201900451SA (en) 2009-03-19 2019-02-27 Chugai Pharmaceutical Co Ltd Pharmaceutical formulation containing improved antibody molecules
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
MX2011010168A (es) 2009-04-07 2011-10-11 Roche Glycart Ag Anticuerpos biespecificos, trivalentes.
AU2010201495B2 (en) 2009-04-16 2012-04-12 Accenture Global Services Limited Touchpoint customization system
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
CA2761891A1 (en) 2009-05-15 2010-11-18 Chugai Seiyaku Kabushiki Kaisha Anti-axl antibody
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
NZ597259A (en) 2009-06-23 2014-04-30 Alexion Pharma Inc Bispecific antibodies that bind to complement proteins
US8945511B2 (en) 2009-06-25 2015-02-03 Paul Weinberger Sensitive methods for detecting the presence of cancer associated with the over-expression of galectin-3 using biomarkers derived from galectin-3
MY199658A (en) 2009-06-26 2023-11-14 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
GB0914691D0 (en) 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
MX336152B (es) 2009-08-29 2016-01-08 Abbvie Inc Proteinas terapeutico de union a dll4.
EP3023438B1 (en) 2009-09-03 2020-03-11 Merck Sharp & Dohme Corp. Anti-gitr antibodies
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
NZ599148A (en) 2009-10-06 2014-08-29 Medimmune Ltd Rsv-specific binding molecule
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
RU2583298C2 (ru) 2009-10-07 2016-05-10 Макродженикс, Инк. ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc-УЧАСТОК, КОТОРЫЕ ДЕМОНСТРИРУЮТ ПОВЫШЕННУЮ ЭФФЕКТОРНУЮ ФУНКЦИЮ БЛАГОДАРЯ ИЗМЕНЕНИЯМ СТЕПЕНИ ФУКОЗИЛИРОВАНИЯ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CN102781963B (zh) 2009-10-27 2018-02-16 Ucb医药有限公司 功能修饰性NAv1.7抗体
CN101875696B (zh) 2009-11-11 2012-02-08 中国人民解放军军事医学科学院生物工程研究所 一种抗体及其制备方法与应用
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
KR101856792B1 (ko) 2009-12-25 2018-05-11 추가이 세이야쿠 가부시키가이샤 폴리펩티드 다량체를 정제하기 위한 폴리펩티드의 개변방법
RS55229B1 (sr) 2009-12-29 2017-02-28 Emergent Product Dev Seattle Heterodimerni vezujući proteini i njihove upotrebe
US8846397B2 (en) 2010-01-20 2014-09-30 Merck Sharp & Dohme Corp. Immunoregulation by anti-ILT5 antibodies and ILT5-binding antibody fragments
EP2525813B1 (en) 2010-01-20 2017-01-04 Merck Sharp & Dohme Corp. Anti-ilt5 antibodies and ilt5-binding antibody fragments
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
EP2528948B1 (en) 2010-01-28 2018-09-19 AB Biosciences, Inc. Novel lowered affinity antibodies and methods of making the same
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
CA2789416A1 (en) 2010-02-09 2011-08-18 Glaxosmithkline Llc Novel uses
ES2826894T3 (es) 2010-02-19 2021-05-19 Xencor Inc Nuevas inmunoadhesinas CTLA4-IG
BR112012022214A2 (pt) 2010-03-01 2017-07-04 Alexion Pharma Inc métodos e composições para tratar doença de degos
EP2543727B1 (en) 2010-03-02 2016-08-31 Kyowa Hakko Kirin Co., Ltd. Modified antibody composition
WO2011108714A1 (ja) 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
TW201206466A (en) 2010-03-11 2012-02-16 Rinat Neuroscience Corp Antibodies with pH dependent antigen binding
JP2011184418A (ja) 2010-03-11 2011-09-22 Tokyo Institute Of Technology 親和性可変抗体
KR20150002894A (ko) 2010-03-11 2015-01-07 리나트 뉴로사이언스 코프. ｐＨ 의존성 항원 결합을 갖는 항체
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
JP5998050B2 (ja) 2010-03-31 2016-09-28 Jsr株式会社 アフィニティークロマトグラフィー用充填剤
BR112012026766B1 (pt) 2010-04-20 2021-11-03 Genmab A/S Métodos in vitro para gerar um anticorpo igg heterodimérico, para a seleção de um anticorpo biespecífico, vetor de expressão, anticorpo igg heterodimérico, composição farmacêutica, e, uso de um anticorpo igg heterodimérico
ES2617777T5 (es) 2010-04-23 2022-10-13 Hoffmann La Roche Producción de proteínas heteromultiméricas
SG185107A1 (en) 2010-04-30 2012-12-28 Alexion Pharma Inc Antibodies having reduced immunogenicity in a human
JP6022444B2 (ja) 2010-05-14 2016-11-09 ライナット ニューロサイエンス コーポレイション ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
WO2011149046A1 (ja) 2010-05-28 2011-12-01 独立行政法人国立がん研究センター 膵癌治療剤
UY33421A (es) 2010-06-03 2011-12-30 Glaxo Wellcome House Proteinas de union al antígeno humanizados
EP2598530A2 (en) 2010-07-29 2013-06-05 Xencor, Inc. Antibodies with modified isoelectric points
CA2808154A1 (en) 2010-08-13 2012-02-16 Medimmmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
PH12013500315A1 (en) 2010-08-16 2013-04-29 Amgen Inc Antibodies that bind myostatin, compositions and methods
WO2012033953A1 (en) 2010-09-08 2012-03-15 Halozyme, Inc. Methods for assessing and identifying or evolving conditionally active therapeutic proteins
WO2012032181A2 (en) 2010-09-10 2012-03-15 Allozyne, Inc Novel antibody derivatives
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
KR101933197B1 (ko) 2010-11-08 2018-12-27 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체
ES2660151T3 (es) 2010-11-17 2018-03-21 Chugai Seiyaku Kabushiki Kaisha Molécula de unión a antígeno multiespecífica que tiene función alternativa a la función del factor VIII de coagulación sanguínea
CN102469096B (zh) 2010-11-19 2015-03-25 奇智软件（北京）有限公司 一种浏览器网银安全加载方法
SG190727A1 (en) 2010-11-30 2013-07-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
AU2011337697B2 (en) 2010-11-30 2016-10-27 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
WO2012088247A2 (en) 2010-12-22 2012-06-28 Medimmune, Llc Anti-c5/c5a/c5adesr antibodies and fragments
JP6043629B2 (ja) 2011-01-07 2016-12-14 中外製薬株式会社 抗体の物性を改善させる方法
SG192945A1 (en) 2011-02-25 2013-09-30 Chugai Pharmaceutical Co Ltd Fcgriib-specific fc antibody
WO2012132067A1 (ja) 2011-03-30 2012-10-04 中外製薬株式会社 抗原結合分子の血漿中滞留性と免疫原性を改変する方法
CN113999307A (zh) 2011-03-30 2022-02-01 中外制药株式会社 改变抗原结合分子的血浆中滞留性和免疫原性的方法
EP3825325A3 (en) 2011-03-30 2021-10-13 Chugai Seiyaku Kabushiki Kaisha Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
WO2012145238A2 (en) 2011-04-20 2012-10-26 Tolerx, Inc. Methods for reducing an adverse immune response to a foreign antigen in a human subject with anti-cd4 antibodies or cd4-binding fragments thereof or cd4-binding molecules
AU2012249454B2 (en) 2011-04-29 2016-03-24 Apexigen, Inc. Anti-CD40 antibodies and methods of use
RS60541B1 (sr) 2011-05-04 2020-08-31 Omeros Corp Kompozicije za inhibiciju masp-2 zavisne aktivacije komplementa
EA033677B1 (ru) 2011-05-21 2019-11-15 Macrogenics Inc Cd3-связывающие молекулы, способные к связыванию с cd3 человека и cd3, не являющимся человеческим
CA2839986A1 (en) 2011-06-20 2012-12-27 St. Louis University Targeting the neuromuscular junction for treatment
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
SG11201401102VA (en) 2011-09-30 2014-09-26 Chugai Pharmaceutical Co Ltd Ion concentration-dependent binding molecule library
US20140335089A1 (en) 2011-09-30 2014-11-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting elimination of antigens
KR102239138B1 (ko) 2011-09-30 2021-04-12 추가이 세이야쿠 가부시키가이샤 표적 항원에 대한 면역응답을 유도하는 항원 결합 분자
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
EP3939996A1 (en) 2011-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
EP3617313A1 (en) 2011-10-05 2020-03-04 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting clearance from plasma of antigen comprising saccharide chain receptor-binding domain
ES2739808T3 (es) 2011-10-27 2020-02-04 Genmab As Producción de proteínas heterodiméricas
MX359775B (es) 2011-10-31 2018-10-10 Chugai Pharmaceutical Co Ltd Molecula enlazada al antigeno que tiene conjugacion regulada entre cadena ligera y cadena pesada.
HUE056462T2 (hu) 2011-11-04 2022-02-28 Zymeworks Inc Stabil heterodimer antestest tervezés mutációkkal az FC domainben
EP3517550A1 (en) 2011-11-30 2019-07-31 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
ES2795419T3 (es) 2012-02-24 2020-11-23 Chugai Pharmaceutical Co Ltd Molécula de unión al antígeno que promueve la desaparición del antígeno vía Fc RIIB
MX351148B (es) 2012-03-08 2017-10-04 Hoffmann La Roche Formulacion de anticuerpo beta amiloide.
JP6273219B2 (ja) 2012-03-13 2018-01-31 ノビミューン エスアー 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
CN107361011B (zh) 2012-03-16 2021-08-27 瑞泽恩制药公司 制备表达ph敏感性免疫球蛋白序列的非人动物的方法
PL2883449T3 (pl) 2012-03-16 2018-07-31 Regeneron Pharmaceuticals, Inc. Przekształcone histydyną łańcuchy lekkie przeciwciał i genetycznie zmodyfikowane gryzonie do wytwarzania tych przeciwciał
JP6280031B2 (ja) 2012-03-29 2018-02-14 中外製薬株式会社 抗ｌａｍｐ５抗体およびその利用
CN104540851B (zh) 2012-03-29 2017-09-15 诺夫免疫股份有限公司 抗tlr4抗体及其用途
TWI619729B (zh) 2012-04-02 2018-04-01 再生元醫藥公司 抗－ｈｌａ－ｂ*２７抗體及其用途
SG10201608307WA (en) 2012-04-20 2016-11-29 Emergent Product Dev Seattle Cd3 binding polypeptides
KR102269650B1 (ko) 2012-04-20 2021-06-28 메뤼스 엔.페. Ig-유사 분자의 제조방법 및 제조수단
EP2844290A4 (en) 2012-05-01 2015-12-16 Glaxosmithkline Llc NOVEL ANTIBODIES
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US20140154270A1 (en) 2012-05-21 2014-06-05 Chen Wang Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography
EP3892638A1 (en) 2012-05-30 2021-10-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens
CA2874721A1 (en) 2012-05-30 2013-12-05 Tomoyuki Igawa Target tissue-specific antigen-binding molecule
WO2013181543A1 (en) 2012-06-01 2013-12-05 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services High-affinity monoclonal antibodies to glypican-3 and use thereof
KR101704893B1 (ko) 2012-06-15 2017-02-08 화이자 인코포레이티드 Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도
SG11201408646VA (en) 2012-07-06 2015-01-29 Genmab Bv Dimeric protein with triple mutations
AU2013302925B2 (en) 2012-08-13 2018-07-05 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies with pH-dependent binding characteristics
AU2013306700B2 (en) 2012-08-24 2019-05-02 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIb-specific Fc region variant
US9133269B2 (en) 2012-08-24 2015-09-15 Anaptysbio, Inc. Humanized antibodies directed against complement protein C5
JP6506554B2 (ja) 2012-09-10 2019-04-24 株式会社カネカ 吸着体、及びそれを用いた精製方法
TWI595007B (zh) 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗ｍｃａｍ抗體及相關使用方法
DK3835310T3 (da) 2012-09-13 2024-06-03 Bristol Myers Squibb Co Fibronektinbaserede skeletdomæneproteiner, der binder til myostatin
TW201418707A (zh) 2012-09-21 2014-05-16 Alexion Pharma Inc 補體組分ｃ５拮抗劑之篩選分析
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US10358492B2 (en) 2012-09-27 2019-07-23 Merus N.V. Bispecific IgG antibodies as T cell engagers
WO2014054804A1 (ja) 2012-10-05 2014-04-10 協和発酵キリン株式会社 ヘテロダイマータンパク質組成物
EP2914634B1 (en) 2012-11-02 2017-12-06 Zymeworks Inc. Crystal structures of heterodimeric fc domains
AU2013341353B2 (en) 2012-11-06 2017-03-16 Children's Medical Center Corporation Compositions and methods for modulating cell signaling
KR101308989B1 (ko) 2012-11-21 2013-09-16 디씨에스이엔지 주식회사 원형재의 면깍기 작업시 최적의 작업조건을 제공하는 면취기 및 면깍기 방법
CN103833852A (zh) 2012-11-23 2014-06-04 上海市肿瘤研究所 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
MX370720B (es) 2012-12-21 2019-12-20 Aveo Pharmaceuticals Inc Anticuerpos anti-gdf15.
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
WO2014114651A1 (en) 2013-01-24 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Tnf-alpha antigen-binding proteins
CN105143261B (zh) 2013-01-31 2021-04-09 首尔大学校产学协力团 C5抗体以及用于预防和治疗补体-相关的疾病的方法
US9481725B2 (en) 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
JP2016516064A (ja) 2013-03-15 2016-06-02 アムジェン インコーポレイテッド ヒト対象におけるミオスタチンの拮抗
HRP20191470T1 (hr) 2013-03-15 2020-01-10 Xencor, Inc. Heterodimerni proteini
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
JP6449229B2 (ja) 2013-03-15 2019-01-09 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｆｃ変異体
US20160031985A1 (en) 2013-03-15 2016-02-04 Katherine S. Bowdish Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
JP6505079B2 (ja) 2013-03-29 2019-04-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法
US11267868B2 (en) 2013-04-02 2022-03-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
SMT202100008T1 (it) 2013-05-06 2021-03-15 Scholar Rock Inc Composizioni e metodi per la modulazione di fattore di crescita
JP6416224B2 (ja) 2013-05-17 2018-10-31 セントル ナショナル デ ラ ルシュルシュ サイエンティフィーク（シーエヌアールエス） 抗ｃｘｃｌ１抗体、抗ｃｘｃｌ７抗体および抗ｃｘｃｌ８抗体ならびにそれらの用途
CN105849129A (zh) 2013-05-31 2016-08-10 酵活有限公司 具有降低的或沉默的效应子功能的异多聚体
CN105722859B (zh) 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
US20160200818A1 (en) 2013-08-14 2016-07-14 Novartis Ag Methods of treating Sporadic Inclusion Body Myositis
EP3033093A1 (en) 2013-08-16 2016-06-22 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
JP6456831B2 (ja) 2013-09-04 2019-01-23 プロテノバ株式会社 イムノグロブリン結合ドメイン多量体
CA2925256C (en) 2013-09-27 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
EP2853898B1 (en) 2013-09-27 2017-01-04 Medizinische Hochschule Hannover Analysis of myostatin in serum
US10501737B2 (en) 2013-09-30 2019-12-10 Chugai Seiyaku Kabushiki Kaisha Method for producing antigen-binding molecule using modified helper phage
SG11201603244VA (en) 2013-11-04 2016-05-30 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
WO2015098357A1 (ja) 2013-12-26 2015-07-02 ソニー株式会社 表示装置
WO2015111008A2 (en) 2014-01-27 2015-07-30 Novartis Ag Biomarkers predictive of muscle atrophy, method and use
WO2015127134A2 (en) 2014-02-20 2015-08-27 Allergan, Inc. Complement component c5 antibodies
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
SG11201607434WA (en) 2014-04-07 2016-10-28 Chugai Pharmaceutical Co Ltd Immunoactivating antigen-binding molecule
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
KR20170017916A (ko) 2014-05-13 2017-02-15 추가이 세이야쿠 가부시키가이샤 면역 억제 기능을 갖는 세포에 대한 t 세포 리다이렉트 항원 결합 분자
TW201625299A (zh) 2014-06-20 2016-07-16 Chugai Pharmaceutical Co Ltd 用於因第ｖｉｉｉ凝血因子及／或活化的第ｖｉｉｉ凝血因子的活性降低或欠缺而發病及／或進展的疾病之預防及／或治療之醫藥組成物
US10183994B2 (en) 2014-06-30 2019-01-22 Merck Patent Gmbh Anti-TNFα antibodies with pH-dependent antigen binding for improved target clearence
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
JP6630036B2 (ja) 2014-09-30 2020-01-15 Jsr株式会社 標的物の精製方法、及び、ミックスモード用担体
HK1243940A1 (zh) 2014-11-06 2018-07-27 Scholar Rock, Inc. 抗原肌肉生长抑制素/潜在肌肉生长抑制素的抗体及其用途
WO2016073906A2 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related immunoassays
SG11201704094QA (en) 2014-12-08 2017-06-29 Novartis Ag Myostatin or activin antagonists for the treatment of sarcopenia
RU2746356C2 (ru) 2014-12-19 2021-04-12 Чугаи Сейяку Кабусики Кайся Антитела к с5 и способы их применения
TWI656133B (zh) 2014-12-19 2019-04-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法
CN107428823B (zh) 2015-01-22 2021-10-26 中外制药株式会社 两种以上抗-c5抗体的组合与使用方法
CA2974547A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses thereof
TWI759261B (zh) 2015-02-27 2022-04-01 日商中外製藥股份有限公司 Ｉｌ－６受體抗體用於製備醫藥組成物的用途
EP3277715A2 (en) 2015-03-31 2018-02-07 Alexion Pharmaceuticals, Inc. Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patients
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
JP6962819B2 (ja) 2015-04-10 2021-11-05 アディマブ， エルエルシー 親ホモ二量体抗体種からのヘテロ二量体多重特異性抗体の精製方法
MX2017013267A (es) 2015-04-15 2018-08-15 Regeneron Pharma Metodos para aumentar la fuerza y funcionalidad con inhibidores del factor de diferenciacion y crecimiento 8 (gdf8).
MX2017010734A (es) 2015-04-17 2017-12-04 Hoffmann La Roche Terapia de combinacion con factores de coagulacion y anticuepos multiespecificos.
JP2018123055A (ja) 2015-04-24 2018-08-09 公立大学法人奈良県立医科大学 血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｘｉ因子（ｆｘｉ）異常症の予防および／または治療に用いられる医薬組成物
EP3288586A1 (en) 2015-05-01 2018-03-07 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of kindney thansplant
EP3313437A1 (en) 2015-06-26 2018-05-02 Alexion Pharmaceuticals, Inc. A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
US10940126B2 (en) 2015-07-03 2021-03-09 Camilla Svensson Inhibition of IL-8 in the treatment of pain and/or bone loss
DK3922645T3 (da) 2015-09-15 2025-06-16 Scholar Rock Inc Anti-pro/latent-myostatin-antistoffer og anvendelse heraf
CN113372443A (zh) 2015-09-18 2021-09-10 中外制药株式会社 Il-8-结合抗体及其应用
TW201718014A (zh) 2015-10-12 2017-06-01 諾華公司 C5抑制劑於移植相關微血管病之用途
JP6088703B1 (ja) 2015-12-18 2017-03-01 中外製薬株式会社 抗ｃ５抗体および使用方法
MY189425A (en) 2015-12-18 2022-02-10 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
JP2019504064A (ja) 2016-01-08 2019-02-14 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 抗プロ／潜在型ミオスタチン抗体およびその使用方法
EP3402816A1 (en) 2016-01-11 2018-11-21 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment
TWI797073B (zh) 2016-01-25 2023-04-01 德商安美基研究（慕尼黑）公司 包含雙特異性抗體建構物之醫藥組合物
MA53248A (fr) 2016-01-25 2022-02-16 Takeda Pharmaceuticals Co Anticorps anti-c5 à commutation ph améliorée
AU2017233658B2 (en) 2016-03-14 2023-09-21 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
CN117205314A (zh) 2016-03-14 2023-12-12 中外制药株式会社 用于癌症治疗的诱导细胞损伤的治疗药物
JP7320943B2 (ja) 2016-04-28 2023-08-04 中外製薬株式会社 抗体含有製剤
KR20210082548A (ko) 2016-06-13 2021-07-05 스칼러 락, 인크. 미오스타틴 억제제의 용도 및 조합 요법
ES2984352T3 (es) 2016-06-14 2024-10-29 Regeneron Pharma Anticuerpos anti-C5 y usos de los mismos
EP3472200A4 (en) 2016-06-17 2020-04-01 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE THEREOF
JP6202774B1 (ja) 2016-06-17 2017-09-27 中外製薬株式会社 抗ｃ５抗体および使用方法
TWI693940B (zh) 2016-08-05 2020-05-21 日商中外製藥股份有限公司 Ｉｌ-８相關疾病之治療用或預防用組成物
KR102365871B1 (ko) 2017-01-31 2022-02-21 추가이 세이야쿠 가부시키가이샤 C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
CA3054067A1 (en) 2017-03-14 2018-09-20 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic ph
EP4236229B1 (en) 2017-03-22 2024-10-16 Mitsubishi Electric R&D Centre Europe B.V. Reference signal for phase tracking insertion
WO2018181870A1 (ja) 2017-03-31 2018-10-04 公立大学法人奈良県立医科大学 血液凝固第ｖｉｉｉ因子の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｉｘ因子異常症の予防および／または治療に用いられる医薬組成物
TWI826364B (zh) 2017-04-03 2023-12-21 德商因夫萊亞斯有限公司 活性抑制劑於發炎性疾病之治療
EA202090641A1 (ru) 2017-09-29 2020-08-07 Чугаи Сейяку Кабусики Кайся Мультиспецифическая антиген-связывающая молекула, обладающая замещающей функциональной активностью кофактора коагулирующего фактора крови viii, и фармацевтическая композиция, содержащая указанную молекулу в качестве активного ингредиента
AU2018354404B2 (en) 2017-10-26 2025-10-30 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS)
WO2019088143A1 (ja) 2017-11-01 2019-05-09 中外製薬株式会社 生物活性が低下した抗体バリアントおよびアイソフォーム
CA3084043A1 (en) 2017-12-04 2019-06-13 Ra Pharmaceuticals, Inc. Modulators of complement activity
TWI704157B (zh) 2018-08-01 2020-09-11 日商中外製藥股份有限公司 在c5相關疾病之治療或預防中使用的醫藥組成物與治療或預防c5相關疾病的方法
TW202509054A (zh) 2019-04-10 2025-03-01 日商中外製藥股份有限公司 Fc區域改變抗體的純化方法
IL305793A (en) 2021-03-12 2023-11-01 Hoffmann La Roche A pharmaceutical preparation for the treatment or prevention of myasthenia gravis
WO2023095305A1 (en) 2021-11-26 2023-06-01 Chugai Seiyaku Kabushiki Kaisha Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006004663A2 (en) * 2004-06-25 2006-01-12 Medimmune, Inc. Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
WO2007114319A1 (ja) * 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CUN. OPIN. DRUG DISCOV. DEVEL., vol. 9, no. 2, 2006, pages 184 - 93
CURR. OPIN. DRUG DISCOV. DEVEL., vol. 9, no. 2, 2006, pages 184 - 93
DE GROOT, A.S. ET AL.: "De-immunization of Therapeutic Proteins by T-cell Epitope Modification.", DEV.BIOL., vol. 122, 2005, pages 171 - 194, XP008074262 *
ONDA, M. ET AL.: "Lowering the Isoelectric Point of the Fv Portion of Recombinant Immunotoxins Leads to Decreased Nonspecific Animal Toxicity without Affecting Antitumor Activity.", CANCER RES., vol. 61, 2001, pages 5070 - 5077, XP008123384 *
VAISITTI, T. ET AL.: "Cationization of monoclonal antibodies: Another step towards the ''Magic Bullet''?", J.BIOL.REGUL.HOMEOST.AGENTS, vol. 19, 2005, pages 105 - 112, XP009125963 *

Cited By (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8062635B2 (en) 2003-10-10 2011-11-22 Chugai Seiyaku Kabushiki Kaisha Bispecific antibody substituting for functional proteins
US20110033452A1 (en) * 2004-10-26 2011-02-10 Chugai Seiyaku Kabushiki Kaisha Anti-Glypican 3 Antibody Having Modified Sugar Chain
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US11168344B2 (en) 2005-03-31 2021-11-09 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US9102739B2 (en) 2005-10-14 2015-08-11 Chugai Seiyaku Kabushiki Kaisha Anti-glypican-3 antibody
US10118959B2 (en) 2005-10-14 2018-11-06 Chugai Seiyaku Kabushiki Kaisha Anti-glypican-3 antibody
US10934344B2 (en) 2006-03-31 2021-03-02 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US12473375B2 (en) 2006-03-31 2025-11-18 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
US9745378B2 (en) 2006-06-08 2017-08-29 Chugai Seiyaku Kabushiki Kaisha Antibodies that bind to cytokine receptor NR10
US9028821B2 (en) 2006-06-08 2015-05-12 Chugai Seiyaku Kabushiki Kaisha Method of treating an inflammatory disease comprising administering an NR 10 antibody antagonist
EP2158315B1 (en) 2007-06-25 2016-03-23 ESBATech, an Alcon Biomedical Research Unit LLC Methods of modifying antibodies, and modified antibodies with improved functional properties
US11248053B2 (en) 2007-09-26 2022-02-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US12116414B2 (en) 2007-09-26 2024-10-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US9688762B2 (en) 2007-09-26 2017-06-27 Chugai Sciyaku Kabushiki Kaisha Modified antibody constant region
US12122840B2 (en) 2007-09-26 2024-10-22 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US11332533B2 (en) 2007-09-26 2022-05-17 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US9828429B2 (en) 2007-09-26 2017-11-28 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US9175091B2 (en) 2007-11-15 2015-11-03 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody capable of binding to anexelekto, and use thereof
US8431127B2 (en) 2007-12-05 2013-04-30 Chugai Seiyaku Kabushiki Kaisha Method for treating pruritus comprising administering an NR10 antagonist
US9399680B2 (en) 2007-12-05 2016-07-26 Chugai Seiyaku Kabushiki Kaisha Nucleic acids encoding anti-NR10 antibodies
US8124725B2 (en) 2007-12-19 2012-02-28 General Electric Company PDGF-Rβ binders
WO2009077569A1 (en) * 2007-12-19 2009-06-25 General Electric Company Biokinetics of fast-clearing polypeptides
US8937047B2 (en) 2007-12-19 2015-01-20 General Electric Company Biokinetics of fast-clearing polypeptides
US20110104157A1 (en) * 2008-04-04 2011-05-05 Chugai Seiyaku Kabushiki Kaisha Liver cancer drug
US11371039B2 (en) 2008-04-11 2022-06-28 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US10472623B2 (en) 2008-04-11 2019-11-12 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
US9868948B2 (en) 2008-04-11 2018-01-16 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US9890377B2 (en) 2008-04-11 2018-02-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US11359194B2 (en) 2008-04-11 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
US8562991B2 (en) 2008-09-26 2013-10-22 Chugai Seiyaku Kabushiki Kaisha Antibody molecules that bind to IL-6 receptor
US10662245B2 (en) 2008-09-26 2020-05-26 Chugai Seiyaku Kabushiki Kaisha Methods of reducing IL-6 activity for disease treatment
WO2010064697A1 (ja) * 2008-12-05 2010-06-10 中外製薬株式会社 抗nr10抗体、およびその利用
WO2010064456A1 (ja) * 2008-12-05 2010-06-10 中外製薬株式会社 抗nr10抗体、およびその利用
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US10066018B2 (en) 2009-03-19 2018-09-04 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
WO2010106812A1 (en) * 2009-03-19 2010-09-23 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical formulation containing improved antibody molecules
US10253091B2 (en) 2009-03-19 2019-04-09 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
WO2010131733A1 (ja) 2009-05-15 2010-11-18 中外製薬株式会社 抗axl抗体
JP5669732B2 (ja) * 2009-05-15 2015-02-12 中外製薬株式会社 抗ａｘｌ抗体
US9340615B2 (en) 2009-05-15 2016-05-17 Chugai Seiyaku Kabushiki Kaisha Anti-AXL antibody
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
EP2470565A4 (en) * 2009-10-23 2013-12-11 Garvan Inst Med Res MODIFIED VARIABLE DOMAIN MOLECULES AND METHODS FOR PRODUCING AND USING THE SAME
JP2013508308A (ja) * 2009-10-23 2013-03-07 ガーバン インスティテュート オブ メディカル リサーチ 修飾可変ドメイン分子、ならびにその産生および使用方法
JP2016175894A (ja) * 2009-11-04 2016-10-06 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 操作型抗ｔｓｌｐ抗体本出願は、米国特許仮出願第６１／２９７，００８号（２０１０年１月２１日出願）、および米国特許仮出願第６１／２５８，０５１号（２００９年１１月４日出願）の利益を主張し、該仮出願は各々、引用によりその全体が本明細書に組み込まれる。
JP2013509862A (ja) * 2009-11-04 2013-03-21 メルク・シャープ・アンド・ドーム・コーポレーション 操作型抗ｔｓｌｐ抗体本出願は、米国特許仮出願第６１／２９７，００８号（２０１０年１月２１日出願）、および米国特許仮出願第６１／２５８，０５１号（２００９年１１月４日出願）の利益を主張し、該仮出願は各々、引用によりその全体が本明細書に組み込まれる。
US11612562B2 (en) 2010-01-20 2023-03-28 Chugai Seiyaku Kabushiki Kaisha Solution preparation containing stabilized antibody
US10022319B2 (en) 2010-01-20 2018-07-17 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing liquid formulations
JP2013518280A (ja) * 2010-01-29 2013-05-20 ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ 凝集体決定法
WO2011092989A1 (ja) 2010-01-29 2011-08-04 東レ株式会社 ポリ乳酸系樹脂シート
WO2011108714A1 (ja) 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
US10435458B2 (en) 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
JP2013529076A (ja) * 2010-05-11 2013-07-18 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｆｇｆｒ２抗体
JP2013539361A (ja) * 2010-07-29 2013-10-24 ゼンコア インコーポレイテッド 改変された等電点を有する抗体
JP2013538059A (ja) * 2010-08-24 2013-10-10 アボット・ラボラトリーズ Ｈｉｖコアタンパク質に特異的な抗体及びその使用
US9334331B2 (en) 2010-11-17 2016-05-10 Chugai Seiyaku Kabushiki Kaisha Bispecific antibodies
US10450381B2 (en) 2010-11-17 2019-10-22 Chugai Seiyaku Kabushiki Kaisha Methods of treatment that include the administration of bispecific antibodies
US11891434B2 (en) 2010-11-30 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US9718882B2 (en) 2010-12-01 2017-08-01 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with P75
US10227402B2 (en) 2010-12-01 2019-03-12 Alderbio Holdings Llc Anti-NGF antibodies and anti-NGF antibody fragments
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9783602B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US10457727B2 (en) 2010-12-01 2019-10-29 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9783601B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US10344083B2 (en) 2010-12-01 2019-07-09 Alderbio Holdings Llc Anti-NGF compositions and use thereof
JP2014507116A (ja) * 2010-12-01 2014-03-27 アルダーバイオ ホールディングス エルエルシー 抗ｎｇｆ組成物およびその使用
US9738713B2 (en) 2010-12-01 2017-08-22 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US10618965B2 (en) 2011-02-25 2020-04-14 Chugai Seiyaku Kabushiki Kaisha Method for altering plasma retention and immunogenicity of antigen-binding molecule
US11718678B2 (en) 2011-02-25 2023-08-08 Chugai Seiyaku Kabushiki Kaisha Method for altering plasma retention and immunogenicity of antigen-binding molecule
JP2014515749A (ja) * 2011-04-21 2014-07-03 ガーバン インスティテュート オブ メディカル リサーチ 修飾された可変ドメイン分子及びその製造及び使用の方法ｂ
WO2012142662A1 (en) 2011-04-21 2012-10-26 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using them b
EP3103810A3 (en) * 2011-04-21 2017-03-08 Garvan Institute of Medical Research Modified variable domain molecules and methods for producing and using them
US11332522B2 (en) 2011-04-21 2022-05-17 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing them
US9527908B2 (en) 2011-04-21 2016-12-27 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing them
US11827699B2 (en) 2011-09-30 2023-11-28 Chugai Seiyaku Kabushiki Kaisha Methods for producing antibodies promoting disappearance of antigens having plurality of biological activities
US10253100B2 (en) 2011-09-30 2019-04-09 Chugai Seiyaku Kabushiki Kaisha Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
US11820793B2 (en) 2011-11-30 2023-11-21 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
WO2013118858A1 (ja) 2012-02-09 2013-08-15 中外製薬株式会社 抗体のFc領域改変体
US12269876B2 (en) 2012-02-09 2025-04-08 Chugai Seiyaku Kabushiki Kaisha Modified Fc region of antibody
EP4624490A2 (en) 2012-02-09 2025-10-01 Chugai Seiyaku Kabushiki Kaisha Modified fc region of antibody
WO2013120929A1 (en) 2012-02-15 2013-08-22 F. Hoffmann-La Roche Ag Fc-receptor based affinity chromatography
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
US10919953B2 (en) 2012-08-24 2021-02-16 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific Fc region variant
US11267868B2 (en) 2013-04-02 2022-03-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
US10782290B2 (en) 2013-06-11 2020-09-22 National Center Of Neurology And Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
US11124576B2 (en) 2013-09-27 2021-09-21 Chungai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
WO2015046554A1 (ja) 2013-09-30 2015-04-02 中外製薬株式会社 改変されたヘルパーファージを用いて抗原結合分子を作製する方法
EP3940065A1 (en) 2013-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Method for producing antigen-binding molecule using modified helper phage
JP7481844B2 (ja) 2013-11-29 2024-05-13 ジェネンテック， インコーポレイテッド 抗体選択装置及び方法
US12444477B2 (en) 2013-11-29 2025-10-14 Genentech, Inc. Antibody selection apparatus and methods
JP2020090504A (ja) * 2013-11-29 2020-06-11 ジェネンテック， インコーポレイテッド 抗体選択装置及び方法
US10227400B2 (en) 2014-03-07 2019-03-12 Alexion Pharmaceuticals, Inc. Methods of treating atypical hemolytic uremic syndrome with anti-C5 antibodies
US10584164B2 (en) 2014-03-07 2020-03-10 Alexion Pharmaceuticals, Inc. Methods of treating atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria with anti-C5 antibodies
US11434280B2 (en) 2014-03-07 2022-09-06 Alexion Pharmaceuticals, Inc. Anti-C5 antibodies having improved pharmacokinetics
US9803007B1 (en) 2014-03-07 2017-10-31 Alexion Pharmaceuticals, Inc. Anti-C5 antibodies having improved pharmacokinetics
US9663574B2 (en) 2014-03-07 2017-05-30 Alexion Pharmaceuticals, Inc. Anti-C5 antibodies having improved pharmacokinetics
US11214623B2 (en) 2014-09-26 2022-01-04 Chugai Seiyaku Kabushiki Kaisha Antibody capable of neutralizing substance having activity alternative to function of coagulation factor VIII (FVIII)
US11001643B2 (en) 2014-09-26 2021-05-11 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
US9975966B2 (en) 2014-09-26 2018-05-22 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing theraputic agent
US12018070B2 (en) 2014-10-15 2024-06-25 Alexion Pharmaceuticals, Inc. Methods of shifting an isoelectric profile of a protein product and uses thereof
WO2016061065A1 (en) * 2014-10-15 2016-04-21 Alexion Pharmaceuticals, Inc. Methods of shifting an isoelectric profile of a protein product and uses thereof
US11440971B2 (en) 2014-11-06 2022-09-13 Hoffmann-La Roche Inc. Fc-region variants with modified FcRn-binding and methods of use
US10683368B2 (en) 2014-11-06 2020-06-16 Hoffmann-La Roche Inc. Fc-region variants with modified FcRn-binding and methods of use
US10738111B2 (en) 2014-12-19 2020-08-11 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
KR20220034918A (ko) 2014-12-19 2022-03-18 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
US9765135B2 (en) 2014-12-19 2017-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-C5 antibodies
US10385122B2 (en) 2014-12-19 2019-08-20 Chugai Seiyaku Kabushiki Kaisha Nucleic acids encoding anti-C5 antibodies
EP4600372A2 (en) 2014-12-19 2025-08-13 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
KR20240042169A (ko) 2014-12-19 2024-04-01 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
US11454633B2 (en) 2014-12-19 2022-09-27 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
US11597760B2 (en) 2014-12-19 2023-03-07 Chugai Seiyaku Kabushiki Kaisha Method of detecting the presence of complement C5
WO2016098357A1 (en) 2014-12-19 2016-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
US10023630B2 (en) 2014-12-19 2018-07-17 Chugai Seiyaku Kabushiki Kaisha Methods of neutralizing C5 with anti-C5 antibodies
US10000560B2 (en) 2014-12-19 2018-06-19 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
US12169205B2 (en) 2014-12-19 2024-12-17 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
KR20210009435A (ko) 2015-02-05 2021-01-26 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
US9969800B2 (en) 2015-02-05 2018-05-15 Chugai Seiyaku Kabushiki Kaisha IL-8 antibodies
JP2022166180A (ja) * 2015-02-05 2022-11-01 中外製薬株式会社 イオン濃度依存的抗原結合ドメインを含む抗体、Ｆｃ領域改変体、ＩＬ－８に結合する抗体、およびその使用
US11180548B2 (en) 2015-02-05 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Methods of neutralizing IL-8 biological activity
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
EP3816179A2 (en) 2015-02-05 2021-05-05 Chugai Seiyaku Kabushiki Kaisha Fc region variant comprising a modified fcrn-binding domain
KR20240090831A (ko) 2015-02-05 2024-06-21 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
US10519229B2 (en) 2015-02-05 2019-12-31 Chugai Seiyaku Kabushiki Kaisha Nucleic acids encoding IL-8 antibodies
US10774148B2 (en) 2015-02-27 2020-09-15 Chugai Seiyaku Kabushiki Kaisha Composition for treating IL-6-related diseases
US12359001B2 (en) 2015-04-01 2025-07-15 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
WO2016167263A1 (ja) * 2015-04-14 2016-10-20 中外製薬株式会社 Ｉｌ－３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
US12441804B2 (en) 2015-04-14 2025-10-14 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient
US10544227B2 (en) 2015-04-14 2020-01-28 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient
EP4650370A2 (en) 2015-04-14 2025-11-19 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
JP2017160178A (ja) * 2015-04-14 2017-09-14 中外製薬株式会社 Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
US11773173B2 (en) 2015-04-14 2023-10-03 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient
JP5954916B1 (ja) * 2015-04-14 2016-07-20 中外製薬株式会社 Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
US10697883B2 (en) 2015-05-19 2020-06-30 National Center Of Neurology And Psychiatry Method for determining application of therapy to multiple sclerosis (MS) patient
TWI751300B (zh) * 2015-09-18 2022-01-01 日商中外製藥股份有限公司 Il-8 結合抗體及其用途
WO2017046994A1 (en) 2015-09-18 2017-03-23 Chugai Seiyaku Kabushiki Kaisha Il-8-binding antibodies and uses thereof
KR20230079500A (ko) 2015-09-18 2023-06-07 추가이 세이야쿠 가부시키가이샤 Il-8에 결합하는 항체 및 그의 사용
KR20250016474A (ko) 2015-09-18 2025-02-03 추가이 세이야쿠 가부시키가이샤 Il-8에 결합하는 항체 및 그의 사용
KR20180125036A (ko) 2015-09-18 2018-11-21 추가이 세이야쿠 가부시키가이샤 Il-8에 결합하는 항체 및 그의 사용
WO2017104783A1 (en) 2015-12-18 2017-06-22 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
US12168697B2 (en) 2015-12-25 2024-12-17 Chugai Seiyaku Kabushiki Kaisha Bispecific antibodies which bind blood coagulation factor VIII and have enhanced activity, and methods of use thereof for treating bleeding and associated conditions
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
US12252532B2 (en) 2015-12-25 2025-03-18 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
US11649262B2 (en) 2015-12-28 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
US12460014B2 (en) 2016-04-28 2025-11-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
US12459992B2 (en) 2016-05-27 2025-11-04 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
KR20220143961A (ko) 2016-06-17 2022-10-25 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체 및 사용 방법
KR20220038530A (ko) 2016-06-17 2022-03-28 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체 및 사용 방법
WO2017217525A1 (en) 2016-06-17 2017-12-21 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
KR20210118979A (ko) 2016-06-17 2021-10-01 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체 및 사용 방법
KR20190009272A (ko) 2016-06-17 2019-01-28 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체 및 사용 방법
US11780912B2 (en) 2016-08-05 2023-10-10 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of IL-8 related diseases
US11053308B2 (en) 2016-08-05 2021-07-06 Chugai Seiyaku Kabushiki Kaisha Method for treating IL-8-related diseases
US11352438B2 (en) 2016-09-06 2022-06-07 Chugai Seiyaku Kabushiki Kaisha Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X
US10844113B2 (en) 2016-09-16 2020-11-24 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use
US10604561B2 (en) 2016-09-16 2020-03-31 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use
US11780908B2 (en) 2016-09-16 2023-10-10 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies, polypeptides containing variant FC regions, and methods of use
US12187786B2 (en) 2016-09-16 2025-01-07 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use
US12371505B2 (en) 2016-12-21 2025-07-29 Teneobio, Inc. Anti-BCMA heavy chain-only antibodies
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
RU2803096C2 (ru) * 2017-06-05 2023-09-06 Янссен Байотек, Инк. Способы модификации поверхностного заряда для получения биспецифических антител
US11365241B2 (en) 2017-07-27 2022-06-21 Alexion Pharmaceuticals, Inc. High concentration anti-C5 antibody formulations
US12012448B2 (en) 2017-07-27 2024-06-18 Alexion Pharmaceuticals, Inc. High concentration anti-C5 antibody formulations
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
US12128101B2 (en) 2017-10-26 2024-10-29 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS)
US12421322B2 (en) 2017-11-01 2025-09-23 Chugai Seiyaku Kabushiki Kaisha Antibody variant and isoform with lowered biological activity
WO2019088143A1 (ja) * 2017-11-01 2019-05-09 中外製薬株式会社 生物活性が低下した抗体バリアントおよびアイソフォーム
JP7777114B2 (ja) 2017-11-01 2025-11-27 中外製薬株式会社 生物活性が低下した抗体バリアントおよびアイソフォーム
JP2024037761A (ja) * 2017-11-01 2024-03-19 中外製薬株式会社 生物活性が低下した抗体バリアントおよびアイソフォーム
JPWO2019088143A1 (ja) * 2017-11-01 2020-11-12 中外製薬株式会社 生物活性が低下した抗体バリアントおよびアイソフォーム
JP7425725B2 (ja) 2017-12-07 2024-01-31 中外製薬株式会社 試料中のポリペプチドの検出または捕捉において使用するための抗体、組成物、および試料中のポリペプチドの検出または捕捉のための方法
JP2021505533A (ja) * 2017-12-07 2021-02-18 中外製薬株式会社 試料中のポリペプチドの検出または捕捉において使用するための抗体、組成物、および試料中のポリペプチドの検出または捕捉のための方法
US11891432B2 (en) 2018-03-15 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use
US12404320B2 (en) 2018-05-31 2025-09-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients
US12460012B2 (en) 2018-06-04 2025-11-04 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS) in pediatric patients
US12312394B2 (en) 2018-06-28 2025-05-27 Alexion Pharmaceuticals, Inc. Methods of producing anti-C5 antibodies
US12240893B2 (en) 2018-10-30 2025-03-04 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH)
JP2024059658A (ja) * 2019-01-03 2024-05-01 アムジエン・インコーポレーテツド 安定性及び生産力価を向上させるためのモノクローナル抗体操作
JP2022544818A (ja) * 2019-08-20 2022-10-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 二重特異性抗体の製剤最適化
US11260125B2 (en) 2019-11-20 2022-03-01 Chugai Seiyaku Kabushiki Kaisha Anti-IL31RA antibody-containing formulations
US11723976B2 (en) 2019-11-20 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Methods of administering anti-IL31A antibody-containing formulations
US12171830B2 (en) 2019-11-20 2024-12-24 Chugai Seiyaku Kabushiki Kaisha Anti-IL-31RA antibody-containing formulations
WO2022025030A1 (ja) 2020-07-28 2022-02-03 中外製薬株式会社 新規改変型抗体を含む、針シールドを備えた針付プレフィルドシリンジ製剤

Also Published As

Publication number Publication date
IL246040A0 (en) 2016-07-31
JP2024057016A (ja) 2024-04-23
EP4368721A2 (en) 2024-05-15
JP2021129579A (ja) 2021-09-09
RU2510400C9 (ru) 2014-07-20
JP6605435B2 (ja) 2019-11-13
AR070716A1 (es) 2010-04-28
US20240190976A1 (en) 2024-06-13
US11248053B2 (en) 2022-02-15
CN106519025B (zh) 2021-04-23
CN106519025A (zh) 2017-03-22
US20250011443A1 (en) 2025-01-09
US12122840B2 (en) 2024-10-22
JP7702024B2 (ja) 2025-07-02
RU2510400C2 (ru) 2014-03-27
US9096651B2 (en) 2015-08-04
EP3127921A1 (en) 2017-02-08
US20110076275A1 (en) 2011-03-31
US20150284465A1 (en) 2015-10-08
JP7381797B2 (ja) 2023-11-16
EP2202245A4 (en) 2010-11-03
CL2009000441A1 (es) 2010-07-02
IL251826A0 (en) 2017-06-29
EP2202245B1 (en) 2016-08-24
CA2700701C (en) 2020-12-29
AU2008304778B2 (en) 2014-01-09
AR128541A2 (es) 2024-05-22
PE20100268A1 (es) 2010-04-21
JP7651031B2 (ja) 2025-03-25
PL2202245T3 (pl) 2017-02-28
JP6232009B2 (ja) 2017-11-15
JP7702023B2 (ja) 2025-07-02
MX336725B (es) 2016-01-28
JP2024133545A (ja) 2024-10-02
JP2024001338A (ja) 2024-01-09
JP2019176871A (ja) 2019-10-17
AR070633A1 (es) 2010-04-21
IL267546A (en) 2019-08-29
KR20100074220A (ko) 2010-07-01
JP5731573B2 (ja) 2015-06-10
CA2700701A1 (en) 2009-04-02
AU2008304778B9 (en) 2014-05-08
MX2010003443A (es) 2010-04-21
SI2202245T1 (sl) 2016-10-28
US20240239906A1 (en) 2024-07-18
MX369784B (es) 2019-11-21
IL246040B (en) 2018-01-31
EP3689912A1 (en) 2020-08-05
JP2013216660A (ja) 2013-10-24
JP2017093444A (ja) 2017-06-01
EP4339294A3 (en) 2024-10-16
EP2202245A1 (en) 2010-06-30
US9828429B2 (en) 2017-11-28
BRPI0817294A2 (pt) 2015-03-17
DK2202245T3 (en) 2016-11-21
TW201738270A (zh) 2017-11-01
JPWO2009041643A1 (ja) 2011-01-27
JP2015130883A (ja) 2015-07-23
AU2008304778A1 (en) 2009-04-02
US12116414B2 (en) 2024-10-15
KR101575914B1 (ko) 2015-12-08
IL267546B (en) 2022-06-01
HUE029635T2 (en) 2017-03-28
RU2010116208A (ru) 2011-11-10
US20220389105A1 (en) 2022-12-08
TWI682938B (zh) 2020-01-21
US20180142027A1 (en) 2018-05-24
CN101874042A (zh) 2010-10-27
JP2024129103A (ja) 2024-09-26
ES2595638T3 (es) 2017-01-02
EP4368721A3 (en) 2024-12-18
CN101874042B (zh) 2018-09-21
IL251826B (en) 2020-02-27
JP2023093571A (ja) 2023-07-04
CN101874042B9 (zh) 2019-01-01
EP4339294A2 (en) 2024-03-20
JP5334319B2 (ja) 2013-11-06
ZA201804148B (en) 2019-09-25
IL204242A (en) 2017-05-29

Similar Documents

Publication Publication Date Title
WO2009041643A1 (ja) Cdrのアミノ酸置換により抗体の等電点を改変する方法
WO2009041062A1 (ja) 血漿中動態が改善されたグリピカン３抗体
WO2011122921A3 (en) An insulin conjugate using an immunoglobulin fragment
WO2011122923A3 (en) Long-acting interferon beta formulation using immunoglobulin fragment
WO2013092983A3 (en) Enzymatic conjugation of polypeptides
EA200970897A1 (ru) Модифицированные лекарственные формы такролимуса
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2009109618A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1
WO2010025321A3 (en) Method for treating multiple sclerosis patients with anti-il2r antibodies
WO2009109616A8 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
WO2007014619A8 (en) Novelimidazolecarboxamide derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
WO2006029845A3 (en) Delivery vehicle containing nanoparticles
WO2009105691A3 (en) Uses of pentamidine and related compounds
WO2011131370A8 (en) Melt-granulated fingolimod
WO2006124413A3 (en) Methods for treating drug resistant cancer
WO2012148148A3 (en) Novel zinc azide complex and a process for preparing tetrazole derivatives using the same
EP2551266A8 (en) 2&#39;,2-dithiazol non-nucleoside compounds, preparation methods, pharmaceutical compositions and uses as hepatitis virus inhibitors thereof
WO2012019428A8 (zh) 二苯甲醇类衍生物、其制备方法及其在医药上的应用
WO2009008414A1 (ja) Ｍｍｐ１３に対する中和活性を有するモノクローナル抗体
WO2012015249A3 (ko) 당뇨병 치료제의 스크리닝 방법
WO2007118680A3 (en) Remedies for ischemia
WO2009028649A1 (ja) アミノ酸高含量固形製剤の低容量化製法
WO2009043577A3 (de) 19-nor-progesterone zur kontrazeption
WO2007084964A3 (en) Pharmaceutical composition comprising a protein pump inhibitor and protein component

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880118639.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08834150

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009534435

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 204242

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2008304778

Country of ref document: AU

Ref document number: 12010500539

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 1740/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2700701

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/003443

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2008834150

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008834150

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008304778

Country of ref document: AU

Date of ref document: 20080926

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20107008915

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010116208

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 12679922

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0817294

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100325

WWE Wipo information: entry into national phase

Ref document number: 246040

Country of ref document: IL